Issue
24
February
2026

E-Newsletter

DCOIWA News

Drugs Control Officers (I) Welfare Association (Regd)

Email: dcoidcwa@gmail.com Website: www.dcoiwa.com

H.Q.: 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S.) India 500072. Phone 8121296397, 8094357800, 9977187574

Monthly Newsletter

For circulation among DCOIWA members only

In collaboration with The Health Master

Published on 1st day of every month

Seminar on "Opportunities and Growth of the Pharmaceutical Industry in Haryana"

Karnal (Haryana)

The Haryana Pharmaceutical Manufacturers Association (HPMA) successfully organized a seminar on the topic of "Opportunities and Growth of the Pharmaceutical Industry in Haryana" on January 11, 2026, at Hotel The Vivanta, NH-44, Karnal. More than 125 pharmaceutical manufacturers from various districts of Haryana participated in the event.

The program began with a welcome address by HPMA President, R.L. Sharma. HPMA General Secretary, Vikas Paruthi, shared the association's achievements over the past two years and highlighted future goals.

He outlined the major problems faced by the industry and presented some important demands to the government and regulatory authorities.

The main demands were as follows:

1. An extension of at least two years for the implementation of the revised Schedule-M for MSME units.

2. Issuance of GMP and GLP certificates from the zonal office, similar to other tender -related certificates.

3. Early establishment of the Karnal Pharma Park to promote investment and employment.

Lalit Kr. Goel, SDC

4. Provision of technical support and guidance to micro and small units for upgradation and compliance.

5. Continuation of the hybrid mode (online + offline) until the ONDLS portal becomes fully functional.

The Chief Guest, MLA Karnal, Jagmohan Anand, appreciated HPMA's efforts and assured his full

(Continued on page 13)

Editorial Board

Editor-in-Chief:

- **Rakesh Dahiya**

Co-Editor:

- **P. K. Jaggi**

Editorial Board:

- **A. Manikandan IAS**
- **Dr. Amal Kumar** (Bihar)
- **Naripen Kumar Goyal** (Haryana)
- **Dr. Arvind. H. Zala** (Gujarat)
- **Dr. Ram Chandra Besra** (Jharkhand)
- **K Limasenla Longchar** (Nagaland)
- **Mijom Lollen** (Arunachal Pradesh)
- **Piyush Jaiswal** (Chhatisgarh)
- **Shabir Ahmad Pandit** (J&K)
- **Dr. Swapnil Patil** (Delhi)
- **Pooran Chand** (Uttar Pradesh)
- **Dr. Jayesh V. Patel** (Gujarat)
- **Suresh Chaudhary** (Haryana)
- **Nandini N** (Karnataka)
- **Sakthivel Ekambaram** (Tamil Nadu)
- **Dr. B Laxmi Narayana** (Telangana)
- **Bhagyashri Yadav** (Maharashtra)
- **Neha Agarwal** (Assam)
- **Dr Kamlesh Kumar Naik** (Himachal Pradesh)
- **Yeshpal Singh** (CDSCO)

Advisory Board:

- **G. Koteshwar Rao** (National President)
- **Lalit Kr. Goel** (Working President)
- **Baldev Choudhry** (Hon. Gen Secretary)

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

DCOIWA NEWS

Rakesh Dahiya

Editor-in-Chief
DCOIWA Newsletter

Two Years of Excellence: Strengthening the Fabric of Drug Regulation

It is with immense pride and a deep sense of responsibility that we present the **24th Edition** of the DCOIWA Newsletter.

This milestone marking exactly two years of consistent, monthly communication arrives on **February 1, 2026 at sharp 9:00 AM**, as a testament to our collective commitment to the professional growth and welfare of the Drugs Control Officer (I) Welfare Association.

As we turn the page into this new chapter, our focus remains steadfast: bridging the gap between policy and practice, while celebrating the human stories behind the regulatory uniforms.

A New Chapter in Leadership

This edition serves as an introduction to the hands that will steer our narrative for the next three years.

We are thrilled to introduce the **Newly Constituted Editorial Board for 2025-2028**. This diverse group of professionals is dedicated to ensuring that every voice in our association is heard.

Alongside this, our National and Working Presidents provide an inspiring "curtain raiser" for the **4th National Annual Congress**, an event that promises to redefine how we collaborate on a national scale.

Recent administrative milestones, such as the **EC Meeting in Chandigarh** and the historic **DCOIWA Founders Meeting**, remind us that our association is built on a foundation of visionary leadership and shared goals.

Strengthening Borders and Standards

Regulation doesn't stop at state lines. The recent meeting between the **FDA Haryana and DCA Himachal Pradesh** represents a significant leap forward in interstate coordination.

By streamlining how we work together, we ensure that the "regulatory net" remains tight and effective.

On the technical front, we delve deep into the updates that are currently shaping our industry:

(Continued on page 4)

(Continued from page 3)

- **Revised Schedule M:** A comprehensive guide on how these changes are strengthening India's regulatory oversight.
- **The Launch of IP 2026:** Exploring the new standards set by the Indian Pharmacopoeia.
- **QR Codes in Pharmacovigilance:** A look at how technology is revolutionizing Adverse Drug Reaction (ADR) reporting.

Celebrating Excellence and Vigilance

Our officers are the silent guardians of public health, and it is only right that their bravery and dedication are recognized.

We are proud to highlight the officers from **Haryana, J&K, Punjab, Tripura, and Telangana** who were honored on Republic Day 2026.

However, vigilance remains our priority. This month, we cover the extensive raids conducted in **Telangana and Haryana**, alongside a detailed list of **NSQ (Not of Standard Quality) drugs** from November 2025.

These reports are not just news; they are essential tools for every officer in the field.

Knowledge at Your Fingertips

In our quest to be a truly helpful resource, this edition is packed with exclusive technical articles, ranging from the regulations surrounding **Codeine Phosphate** to the procedural nuances of licensing **Commercial Testing Laboratories**. We've also included a "Laughter

ose" and a collection of "FDA Memorable Moments" to remind us that while our work is serious, our community is a family.

As we look toward the 4th National Annual Congress, let this newsletter be your guide and your forum.

We are more than just regulators; we are the frontline of safety in a rapidly evolving pharmaceutical landscape.

Happy Reading, and stay vigilant.

Editorial Board Members 2025-2028

DCOIWA's EDITORIAL BOARD FOR THE PERIOD 2025-28

Editor in chief
Rakesh Dahiya
(Haryana)
Mob: 9911600019

Co Editor
P K Jaggi
(Delhi)
Mob: 98111 68062

Member
A Manikandan IAS
(Uttar Pradesh)
Mob: 9444061429

Member
Dr. Amal Kumar
(Bihar)
Mob: 7781909777

Member
Naripen Kumar Goyal
(Haryana)
Mob: 8396840917

Member
Dr. Arvind H. Zala
(GUJARAT)
Mob: 7567513712

Member
Dr Ram Chandra Besra
(Jharkhand)
Mob: 8709837191

Member
K. Limasenla Longchar
(Nagaland)
Mob: 9862782700

Member
Mr. Mijom Iollen
(Arunachal Pradesh)
Mob: 9436254165

Member
Mr. Piyush Jaiswal
(Chhattisgarh)
Mob: 97533 77555

Member
Shabir Ahmad Pandith
(Jammu & Kashmir)
Mob: 9596378803

Member
Dr. Swapnil Patil
(Delhi)
Mob: 9146022074

Member
Mr. Pooran Chand
(Uttar Pradesh)
Mob: 97603 66100

Member
Dr. Jayesh V. Patel
(Gujarat)
Mob: 9998690815

Member
Mr. Suresh Choudhary
(Haryana)
Mob: 89504 62574

Member
Mrs. Nandini N
(Karnataka)
Mob: 8951206152

Member
Mr. Sakthivel Ekambaram
(Tamilnadu)
Mob: 9791768450

Member
Dr. B Laxmi Narayana
(Telangana)
Mob: 7981738375

Member
Mrs. Bhagyashri Yadav
(Maharashtra)
Mob: 7875487550

Member
Mrs. Neha Agarwal
(Assam)
Mob: 9678993014

Member
Dr. Kamlesh Kumar Naik
(Himachal Pradesh)
Mob: 9418368107

Member
Mr. Yeshpal Singh
(CDSCO)
Mob: 9205606917

ADVISORY BOARD

G. KOTESHWAR RAO
National President
Telangana
Mob: 8121296397
inspectordrugs@gmail.com

LALIT KR. GOEL
Working President
Haryana
Mob: 7056702999
fdazone@gmail.com

BALDEV CHOUDHARY
Gen. Secretary
Mob: 8094357800
dcobaldevchoudhary
@gmail.com

Message from Editorial Board: DCOIWA News

31st January 2026,

Panchkula, Haryana.

Dear Esteemed Members of DCOIWA,

Thank you very much for your continuous support in making our DCOIWA News "e-Newsletter" reach all members every month, punctually on the first day at 9:00 AM.

Your encouragement and cooperation have been the key strength behind this consistency.

We take this opportunity to express my sincere gratitude to the Editorial Board members (2022–2025) for their valuable support and timely inputs, which have greatly contributed to the quality and success of the newsletter.

As per the guidance of our National President, Shri G Koteshwar Rao Ji, and Working President, Shri Lalit Kr. Goel Ji, and also based on requests from a few present board members, we have reshuffled the Editorial Board (2025-28) by adding a few new members and relieving a few existing ones, with the objective of ensuring better administration and efficiency.

The list of the newly constituted Editorial Board will be announced in the February Newsletter.

With sincere thanks and warm regards,

Rakesh Dahiya
Editor-in-Chief

P. K. Jaggi
Co-Editor

President's Note cum curtain raiser for 4th National Annual Congress

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President	President	Working President
Dr. HEMANT G. KOSHIA	G. KOTESHWAR RAO	LALIT KUMAR GOEL
99784 05054, Gujarat - LM 821	8121296397, Telangana - LM 001	70567 02999, Haryana - LM 002
Organizing Secretary:	**General Secretary:**	**Treasurer:**
Rakesh Dahiya	Baldev Choudhary	Dr. Parmanand Verma
99116 00019, Haryana - LM 003	8094357800, Rajasthan - LM 004	9977177574, Chhattisgarh - LM 005

Vice-Presidents:
M. Dhilip Kumar, 9840071715, Tamilnadu - LM 06
M. Amrutha Rao, 79932 57834, Telangana - LM 712
D. R. Gahane, 98928 32289, Maharashtra - LM 623
V. D. Dobaria, 98790 60666, Gujarat - LM 1044
Dr. Manish Kapoor, 9418081270, H. P. - LM 16
Dr. Dharmesh Agrawal, 9824500354, Daman & Diu - LM 874
Deepak Sharma, 98103 00958, Delhi - LM 961
Dr. S. Umesh, 94480 54321, Karnataka - LM 816
Sushant Sharma (CDSCO), 82849 37441 - LM 398

Joint Secretaries:
Chandan Kumar Giri, 8895478543, Odisha - LM 10
Biswajit Talukdar, 7086084833, Assam - LM 235
Pooran Chand, 9760366100, Uttar Pradesh - LM 11
Dr. Arvind Zala, 75675 13712, Gujarat - LM 1051
Dr. E. Ananda Kirouchenane, 9443957680, Puducherry - LM 15
Bangaru Rajan, 84472 16636, CDSCO - LM 813
Rajkumar V. Zadbuke, 9892827738, Maharashtra - LM 17
Sanjiv Kumar, 9501005278, Punjab - LM 311
Tapan Kumar Chaudhuri, 9230610226, West Bengal- LM 9

Date: 1st February 2026,
Place: Hyderabad.

PRESIDENT'S NOTE CUM
CURTAIN RAISER FOR 4TH ANNUAL CONGRESS

Dear Esteemed Members of DCOIWA,

Warm greetings to all of you.

I am pleased to address you through the February 2026 edition of our DCOIWA Newsletter. I take this opportunity to sincerely thank all our members for their continued support, encouragement, and active participation in strengthening our association.

It gives me immense pleasure to inform you about the formation of the DCOIWA Advisory Committee (2025–28) under the able Chairmanship of Shri N. K. Ahooja and Shri K. R. Chawla as Co-Chairman, along with other eminent personalities from the Drugs Control Department. Their vast experience and guidance will certainly provide valuable direction to DCOIWA in achieving its objectives more effectively.

I am also happy to announce the formation of the Editorial Board (2025–28) under the leadership of Shri Rakesh Dahiya as Editor-in-Chief and Shri P. K. Jaggi as Co-Editor. I am confident that the new editorial team will further enhance the quality, content, and reach of our Newsletter, making it more informative and impactful for all members.

Curtain Raiser – 4th Annual Congress of DCOIWA
As a curtain raiser, I am delighted to inform you that the 4th Annual Congress of DCOIWA is scheduled to be held on 11th & 12th July 2026 at Daman. This prestigious event will be jointly organized by Gujarat and Daman, under the Chairmanship of Shri V. D. Dobaria, with Shri Dharmesh Agarwal as Co-Chairman.

The Annual Congress will serve as an important platform for professional interaction, knowledge sharing, and strengthening the bond among Drugs Control Officers across the country. Detailed information regarding the theme, program schedule, registration, and other arrangements will be shared with you shortly.

I request all members to extend their wholehearted cooperation and make this event a grand success.

With best wishes and warm regards,

Yours sincerely,

G. Koteshwar Rao
National President
DCOIWA

Lalit Kr. Goel
Working President
DCOIWA

EC Members:
Garima Sharma, 9418086497, H.P. - LM 228
Dipika Chauhan, 7990351251, Gujarat - LM 13
Dr. Mahalakshmy .R, 9497004156, Kerala - LM 19
Navdeep Kaur, 98153 47179, Punjab - LM 1722
Anamika Ankur Jain, 99977 99722, U. P. - LM 1663
Dr. Amal Kumar, 77819 09777, Bihar - LM 56
Kanchan Sinha, 97745 48986, Tripura - LM 22
Ibom Ete, 8414819858, A.R. - LM 23
Iarap T. D. Toi, 9233323204, Meghalaya - LM 07
Dr. Zaffer Ahmad, 7298009092, J & K - LM 20
M.Chandra Sekhara Rao, 94901 53316, A. P. - LM 1672
Amit Kumar Bansal, 9198463261, U. P. - LM 14
Venkatesh Sinari, 98506 08501, Goa - LM 08

H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800,9977177574.

Minutes of EC Meeting 10-01-2026

1

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Date: 10-01-2026

Place: Chandigarh

Minutes of the 1st EC Meeting of Newly Elected Body for 2025-28

(Founder Members)

Attendees (Physical)

1. G. Koteshwar Rao
2. Baldev Choudhary
3. Manish Kapoor
4. Dhilip Kumar

Attendees (Online)

1. Dr. E. Anandakirouchenane
2. Parmanand Verma
3. Chandan Kumar Giri

Special Invitees

1. Lalit Kr. Goel
2. Rakesh Dahiya

This Special meeting is held under the Chairmanship of Shri Lalit Goel (Founder of DCOIWA) after observing 2 minutes of mourning in memory of Late Shri Amit Kumar, DI, Jharkhand.

Agenda of the meeting:

1) To present half year audit report of DCOIWA & DCOIWT (1st April 2025 to 31st Oct. 2025)
2) To reshuffle and expand the executive committee.
3) To discuss about 4th Annual Congress
4) To Discuss about future activities of the Association
5) Any other matter with the permission of chair.
6) Vote of thanks.

Minutes of EC Meeting 10-01-2026

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Welcome Address:

- (1) Shri Rakesh Dahiya, founder member of DCOIWA, welcomed all the delegates and requested Shri Lalit Goel (Founder of DCOIWA) to chair the meeting.
- (2) Shri Lalit Goel, after taking the chair, congratulated all the 7 DCOIWA founder members for re-election for the year 2025-2028. He appreciated the work done by the previous committee.

Agenda 1:

G. Koteshwar Rao, National President, presented the half-yearly audited financial report (1-4-2025 to 31st Oct 2025) of the Association & Trust.

- He thanked all the CEC members and state EC members for coordinating the 3rd Annual Congress and making it a grand success held in the month of July 2025 at Ramoji Film City, Hyderabad.
- He further explained the status of office building construction, which will be handed over in another 2 or 3 months.

Agenda 2:

The responsibility to reconstruct the Central Committee is given to Chairman Shri Lalit Goel. After discussing with all other members based on future requirements, the following members were taken into the Central Committee for better administration:

1. Honorary President : **Shri Hemant G. Koshia** (Gujarat)
2. Working President : **Shri Lalit Kr. Goel** (Haryana)
3. President : **Shri G. Koteshwar Rao** (Telangana)
4. Organizing Secretary : **Shri Rakesh Dahiya** (Haryana)
5. General Secretary : **Shri Baldev Choudhary** (Rajasthan)
6. Treasurer : **Shri Parmanand Verma** (Chhattisgarh)

Minutes of EC Meeting 10-01-2026

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President	President	Working President
Dr. HEMANT G. KOSHIA	G. KOTESHWAR RAO	LALIT KUMAR GOEL
99784 05054, Gujarat - LM 821	8121296397, Telangana - LM 001	70567 02999, Haryana - LM 002
Organizing Secretary:	**General Secretary:**	**Treasurer:**
Rakesh Dahiya	Baldev Choudhary	Dr. Parmanand Verma
99116 00019, Haryana - LM 003	8094357800, Rajasthan - LM 004	9977177574, Chhattisgarh - LM 005

Vice-Presidents:
M. Dhilip Kumar
9840071715,
Tamilnadu - LM 06
M. Amrutha Rao
79932 57834,
Telangana - LM 712
D. R. Gahane
98928 32289,
Maharashtra - LM 623
V. D. Dobaria
98790 60666,
Gujarat - LM 1044
Dr. Manish Kapoor
9418081270
H. P. - LM 16
Dr. Dharmesh Agrawal
9824500354
Daman & Diu - LM 874
Deepak Sharma
98103 00958
Delhi - LM 961
Dr. S. Umesh
94480 54321
Karnataka - LM 816
Sushant Sharma (CDSCO)
82849 37441 - LM 398
Joint Secretaries:
Chandan Kumar Giri
8895478543
Odisha - LM 10
Biswajit Talukdar
7086084833
Assam - LM 235
Pooran Chand
9760366100
Uttar Pradesh - LM 11
Dr. Arvind Zala
75675 13712
Gujarat - LM 1051
Dr. E. Ananda Kirouchenane
9443957680
Puducherry - LM 15
Bangaru Rajan
84472 16636
CDSCO - LM 813
Rajkumar V. Zadbuke
9892827738
Maharashtra - LM 17
Sanjiv Kumar
9501005278
Punjab - LM 311
Tapan Choudhry
9230610226
West Bengal- LM 9

6. Vice Presidents

1. Shri Dhilip Kumar (Tamil Nadu)
2. Shri M. Amrutha Rao (Telangana)
3. Shri D. R. Gahane (Maharashtra)
4. Shri V. D. Dobaria (Gujarat)
5. Dr. Manish Kapoor (Himachal Pradesh)
6. Dr. Dharmesh Agrawal (Daman & Diu)
7. Shri Deepak Sharma (Delhi)
8. Dr. Umesh S. (Karnataka)
9. Shri Sushant Sharma (CDSCO)

Joint Secretaries

1. Shri Chandan Kumar Giri (Odisha)
2. Shri Biswajit Talukdar (Assam)
3. Shri Puran Chand (Uttar Pradesh)
1. Dr. Arvind Zala (Gujarat)
2. Dr. E. Anandakirouchenane (Puducherry)
3. Shri Bangarurajan (CDSCO)
4. Shri Raj Kumar V. Zadbuke (Maha)
5. Shri Sanjiv Kumar (Punjab)
6. Shri Tapan Chaudhry (WB)

E.C. Members

1. Smt. Garima Sharma (HP)
2. Smt. Dipika Chauhan (Gujarat)
3. Smt. Mahalakshmi (Kerala)
4. Smt. Navdeep Kaur (Punjab)
5. Smt. Anamika Ankur Jain (UP)

EC Members:
Garima Sharma
9418086497
H.P. - LM 228
Dipika Chauhan
7990351251
Gujarat - LM 13
Dr. Mahalakshmy .R
9497004156
Kerala - LM 19
Navdeep Kaur
98153 47179
Punjab - LM 1722
Anamika Ankur Jain
99977 99722
U. P. - LM 1663
Dr. Amal Kumar
77819 09777
Bihar - LM 56
Kanchan Sinha
97745 48986
Tripura - LM 22
Ibom Ete
8414819858
A.R. - LM 23
Iarap T. D. Toi
9233323204
Meghalaya - LM 07
Dr. Zaffer Ahmad
7298009092
J & K - LM 20
M.Chandra Sekhara Rao
94901 53316
A. P. - LM 1672
Amit Kumar Bansal
9198463261
U. P. - LM 14
Venkatesh Sinari
98506 08501
Goa - LM 08

H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800,9977177574.

Minutes of EC Meeting 10-01-2026

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

4

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President	President	Working President
Dr. HEMANT G. KOSHIA	G. KOTESHWAR RAO	LALIT KUMAR GOEL
99784 05054, Gujarat - LM 821	8121296397, Telangana - LM 001	70567 02999, Haryana - LM 002
Organizing Secretary:	**General Secretary:**	**Treasurer:**
Rakesh Dahiya	Baldev Choudhary	Dr. Parmanand Verma
99116 00019, Haryana - LM 003	8094357800, Rajasthan - LM 004	9977177574, Chhattisgarh - LM 005

Vice-Presidents:
M. Dhilip Kumar
9840071715,
Tamilnadu - LM 06
M. Amrutha Rao
79932 57834,
Telangana - LM 712
D. R. Gahane
98928 32289,
Maharashtra - LM 623
V. D. Dobaria
98790 60666,
Gujarat - LM 1044
Dr. Manish Kapoor
9418081270
H. P. - LM 16
Dr. Dharmesh Agrawal
9824500354
Daman & Diu - LM 874
Deepak Sharma
98103 00958
Delhi - LM 961
Dr. S. Umesh
94480 54321
Karnataka - LM 816
Sushant Sharma (CDSCO)
82849 37441 - LM 398

Joint Secretaries:
Chandan Kumar Giri
8895478543
Odisha - LM 10
Biswajit Talukdar
7086084833
Assam - LM 235
Pooran Chand
9760366100
Uttar Pradesh - LM 11
Dr. Arvind Zala
75675 13712
Gujarat - LM 1051
Dr. E. Ananda Kirouchenane
9443957680
Puducherry - LM 15
Bangaru Rajan
84472 16636
CDSCO - LM 813
Rajkumar V. Zadbuke
9892827738
Maharashtra - LM 17
Sanjiv Kumar
9501005278
Punjab - LM 311
Tapan Choudhry
9230610226
West Bengal- LM 9

6. Dr. Amal Kumar (Bihar)
7. Smt. Kanchan Sinha (Tripura)
8. Shri Ibom Ete (Arunachal Pradesh)
9. Shri Iarap T.D. Toi (Meghalaya)
10. Shri Zaffer Ahmed (J & K)
11. Shri M. Chandra Shekhar Sekhar (Andhra Pradesh)
12. Shri Amit Bansal (UP)
13. Dr. Shri Venkatesh Simari (Goa)

Agenda – 3

Regarding 4th Annual Congress, which is decided during 3rd Congress, will be conducted jointly by Gujarat & Daman at Daman in July 2026 (11th & 12th July 2026).

It is decided to visit the place once soon by Shri Lalit Goel & Shri G. Koteshwar Rao.

It is unanimously decided to nominate Shri V. D. Dobaria as Chairman of LOC.

Agenda – 4

Future Activities

It was decided to conduct awareness programmes at Chandigarh (for Haryana, Punjab, and UT Chandigarh) in February/March 2026, and also at Rajasthan, Uttar Pradesh, Bihar, and West Bengal.

Agenda – 5

Any Other Matters

(i) On the request of the National President, Smt. Navdeep Kaur, DI, Punjab, who has been selected as "Mrs. Supra National" and honoured during the meeting.

EC Members:
Garima Sharma
9418086497
H.P. - LM 228
Dipika Chauhan
7990351251
Gujarat - LM 13
Dr. Mahalakshmy .R
9497004156
Kerala - LM 19
Navdeep Kaur
98153 47179
Punjab - LM 1722
Anamika Ankur Jain
99977 99722
U. P. - LM 1663
Dr. Amal Kumar
77819 09777
Bihar - LM 56
Kanchan Sinha
97745 48986
Tripura - LM 22
Ibom Ete
8414819858
A.R. - LM 23
Iarap T. D. Toi
9233323204
Meghalaya - LM 07
Dr. Zaffer Ahmad
7298009092
J & K - LM 20
M.Chandra Sekhara Rao
94901 53316
A. P. - LM 1672
Amit Kumar Bansal
9198463261
U. P. - LM 14
Venkatesh Sinari
98506 08501
Goa - LM 08

H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800,9977177574.

Minutes of EC Meeting 10-01-2026

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

5

Honorary President	President	Working President
Dr. HEMANT G. KOSHIA	G. KOTESHWAR RAO	LALIT KUMAR GOEL
99784 05054, Gujarat - LM 821	8121296397, Telangana - LM 001	70567 02999, Haryana - LM 002
Organizing Secretary:	**General Secretary:**	**Treasurer:**
Rakesh Dahiya	Baldev Choudhary	Dr. Parmanand Verma
99116 00019, Haryana - LM 003	8094357800, Rajasthan - LM 004	9977177574, Chhattisgarh - LM 005

Vice-Presidents:
M. Dhilip Kumar
9840071715,
Tamilnadu - LM 06
M. Amrutha Rao
79932 57834,
Telangana - LM 712
D. R. Gahane
98928 32289,
Maharashtra - LM 623
V. D. Dobaria
98790 60666,
Gujarat - LM 1044
Dr. Manish Kapoor
9418081270
H. P. - LM 16
Dr. Dharmesh Agrawal
9824500354
Daman & Diu - LM 874
Deepak Sharma
98103 00958
Delhi - LM 961
Dr. S. Umesh
94480 54321
Karnataka - LM 816
Sushant Sharma (CDSCO)
82849 37441 - LM 398

Joint Secretaries:
Chandan Kumar Giri
8895478543
Odisha - LM 10
Biswajit Talukdar
7086084833
Assam - LM 235
Pooran Chand
9760366100
Uttar Pradesh - LM 11
Dr. Arvind Zala
75675 13712
Gujarat - LM 1051
Dr. E. Ananda Kirouchenane
9443957680
Puducherry - LM 15
Bangaru Rajan
84472 16636
CDSCO - LM 813
Rajkumar V. Zadbuke
9892827738
Maharashtra - LM 17
Sanjiv Kumar
9501005278
Punjab - LM 311
Tapan Choudhry
9230610226
West Bengal- LM 9

(ii) The President wants to conduct a grand farewell party at Chandigarh in the last week of March 2026 during the CEC meeting to Shri Lalit Goel (Founder, DCOIWA) and all the members approved it.

Agenda – 6

Vote of Thanks

The meeting concluded with a vote of thanks presented by Shri Manish Kapoor.

G. Koteshwar Rao
President

Lalit Kr. Goel
Working President

Rakesh Dahiya
Org. Secretary

Baldev Choudhary
Gen. Secretary

EC Members:
Garima Sharma
9418086497
H.P. - LM 228
Dipika Chauhan
7990351251
Gujarat - LM 13
Dr. Mahalakshmy .R
9497004156
Kerala - LM 19
Navdeep Kaur
98153 47179
Punjab - LM 1722
Anamika Ankur Jain
99977 99722
U. P. - LM 1663
Dr. Amal Kumar
77819 09777
Bihar - LM 56
Kanchan Sinha
97745 48986
Tripura - LM 22
Ibom Ete
8414819858
A.R. - LM 23
Iarap T. D. Toi
9233323204
Meghalaya - LM 07
Dr. Zaffer Ahmad
7298009092
J & K - LM 20
M.Chandra Sekhara Rao
94901 53316
A. P. - LM 1672
Amit Kumar Bansal
9198463261
U. P. - LM 14
Venkatesh Sinari
98506 08501
Goa - LM 08

H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800,9977177574.

Seminar on "Opportunities and Growth of the Pharmaceutical Industry in Haryana"

(Continued from page 1)

support.

He said that he would raise all these demands with the state government and would take up the demand for an extension in the revised Schedule-M with the central government through Union Minister Manohar Lal Khattar.

He also assured that he would seriously pursue the demand for the Pharma Park.

Lalit Goyal, State Drug Controller, Haryana, provided detailed information on the guidelines of the revised Schedule-M and emphasized maintaining quality standards.

Dr. Ajay Sachan, Deputy Drug Controller (India), shared his views on export opportunities and regulatory coordination.

Ripan Mehta, Deputy State Drug Controller, emphasized the need to strengthen cooperation between regulators and the industry.

The program concluded with a vote of thanks by Mr. Rajiv Garg, Executive Member of HPMA.

Rakesh Dahiya, Asstt. State Drugs Controller, Sunil Chaudhary, SDCO, Gurcharan Singh along with Drugs Control Officers of the FDA Haryana were also present in the event.

This seminar served as a strong platform for dialogue between the industry and regulators and reaffirmed HPMA's commitment to the sustainable development of the pharmaceutical industry in the state.

Source: FDA Haryana

DCOIWA Founders meeting at Chandigarh

DCOIWA in News

11th January 2026
Chandigarh.

The Drugs Control Officers' Indian Welfare Association (DCOIWA) congratulated and honored Smt. Navdeep Kaur, Drugs Control Officer, Punjab, on her recent achievement of being awarded Mrs. Supranational.

The felicitation was attended by Shri Lalit Goel, Shri Rakesh Dahiya, Shri Dhilip Kumar, Shri Baldev Chowdhry, and Shri G. Koteshwar Rao.

On this occasion, all present extended their heartfelt congratulations and wished her continued success and many more such accolades in the future

DCOIWA in News



Meeting of State Regulatory Heads of FDA Haryana and DCA Himachal Pradesh on 10-01-2026 to streamline interstate co-ordination.

Glimpse of Seminar by International Pharma Federation

Indian Pharmacopoeia: IP 2026 Released



Codeine Phosphate and its Regulations in India

1

Lalit Kr. Goel

State Drugs Controller,

FDA Haryana

Codeine Phosphate

Codeine Phosphate

Know all about Codeine Phosphate and its preparations and Download all notifications related to Codeine Phosphate, the links are given below:

1. Codeine Phosphate:

An official drug listed in the Indian Pharmacopoeia (IP).

2. Dosage Forms:

Primarily available in syrups and tablets.

3. Narcotic Drug Classification:

Codeine Phosphate API is classified as a Narcotic Drug under the Narcotic Drugs & Psychotropic Substances Act, 1985 (NDPS Act).

4. Drugs and Cosmetics Act Coverage:

Codeine Phosphate and its formulations are included in Schedule H1 of the Drugs and Cosmetics Act, 1940 (serial number 20).

5. Manufactured Drug Status:

Notified as a "Manufactured Drug" under the NDPS Act, 1985 (serial no. 35 vide notification S.O. no. 826 (E) dated 14.11.1985).

6. Quota Allotment for Purchase and Use:

Allopathic Drug Manufacturers require a quota allotment issued by the Excise & Taxation Department for purchasing and using Codeine Phosphate API.

7. Exemptions from NDPS Act:

- Codeine Phosphate formulations:
- Up to 100mg per dosage unit.
- Up to 2.5% concentration in undivided preparations.
- Exempt from NDPS Act, 1985, subject to compliance with Drugs and Cosmetics Act (1940) and Rules (1945).

8. Plain Codeine Phosphate:

Covered under the NDPS Act, 1985 (without combination with other drugs).

9. Drug Sale License Requirement:

A Drugs Sale License (Retail/Wholesale) under the Drugs Act is mandatory for selling Codeine Phosphate formulations.

10. Storage, Possession, Sale, and Distribution License:

A license issued under the provisions of State NDPS Rules of the respective State Government is required.

11. Record Keeping:

Licensees must maintain sale/purchase records of Codeine Phosphate. Failure to do so is a contravention of Rule 65A of the

(Continued on page 20)

Codeine Phosphate and its Regulations in India 2

(Continued from page 19)

NDPS Act, 1985.

12. Unlicensed Activities:

Unlicensed manufacturing, stocking, and sale of Codeine Phosphate and its formulations are offenses under the NDPS Act, 1985.

13. Offence Severity for Unlicensed Stocking:

- Depends on the quantity:
- Small quantity: 10 grams (vide notification S.O. no. 1055 (E) dated 19.10.2001).
- Commercial quantity: 1.0 kilogram.

Codeine Phosphate

14. Labeling Requirements:

- "NRx" labeling is mandatory for single-ingredient Codeine Phosphate drugs.
- Not mandatory for formulations/Fixed Dose Combinations (with other drugs) if the condition specified at serial number 35 of the NDPS Act is fulfilled.

15. Banned Combination:

Fixed Dose Combination of Codeine Phosphate + Chlorpheniramine Maleate + Menthol Syrup (vide notification S.O. no. 2404 dated 02.06.2023).

16. Essential Narcotic Drug:

Codeine (narcotic drug) is notified as an essential narcotic drug for medical and scientific use (vide notification S.O. no. 1181 (E) dated 05.05.2015).

17. Possession by Medical Practitioners:

A Registered Medical Practitioner can possess up to 2,000mg (equivalent to 2 grams) of narcotic drugs for use in their practice, not for sale or distribution.

18. Codeine Stock by Recognized Medical Institutes:

Vide notification GSR 359 (E) dated 05.05.2015, recognized medical institutes can possess codeine upon approval from the State Drugs Controller of the State.

Click here for more article of the Author

Procedure to obtain license for Commercial Testing Laboratories

1

Rakesh Dahiya

Editor-in-Chief,
DCOIWA News
Organising Secretary,
DCOIWA
Asstt. State Drugs Controller,
FDA Haryana

How to obtain License for Commercial Testing Laboratories

We have provided the procedure to obtain license for commercial testing laboratories, documents required, application form, fee required, conditions of licenses and procedure for retention fee etc.

Documents required

For obtaining license for Commercial Testing Laboratory, the list of documents required is provided below. Download the pdf file and prepare the documents accordingly.

Documents-required-for-obtaining-Lab-license

Procedure for obtaining license

Procedure for obtaining license for Commercial Testing Laboratory. Download the pdf file for more detail and prepare the documents accordingly.

Procedure-for-obtaining-Lab-license

Application Form

List of Forms & Fee for obtaining the said license is provided below. Download the pdf file and prepare the Form accordingly and submit the required fee.

Form-36

Download the below pdf file

Form-36

For Cosmetics

Form-Cos-22

For Medical Devices

Form-MD-39

Download fee structure

Click below link to download the fee structure of all types of drug licenses

License fee structure for all licenses

(Continued on page 22)

Procedure to obtain license for Commercial Testing Laboratories

2

(Continued from page 21)

Download area requirement

Click below link to download the requirement for the manufacturing of Drugs, Cosmetics, Homoeopathic and Blood Centre

Area requirement for manufacturing

Schedule L 1

Schedule-L-1

Submit your application (Online and / or hard copy) to State Drugs Controller / Licensing Authority of your area after completing all the required documents.

Note: Requirements of some of documents and procedure for submission of application may vary from State to State

Requirement and condition of license

Conditions of licenses is to be maintained after obtaining the required license for Commercial Testing Laboratory. Download the pdf file for ready reference.

Requirements-and-Conditions-of-Commercial-Testing-Laboratory

License retention fee

Procedure for submission of license retention fee. Download the pdf file for more detail and prepare the documents accordingly.

Procedure-for-License-retention-fee

Compiled by:

Rakesh Dahiya

Asstt. State Drugs Controller

FDA Haryana

Click here for more articles of the Author

Strategic Implementation of QR Codes in ADR: A Mandate for Next-Generation Pharmacovigilance in India

1

Dr. Bharatesh R Jagashetty

Former National Adviser (Drugs Control) to MoHFW, GOI & CDSCO | Former State Drugs Controller, FDA Karnataka |

The Imperative for Systemic Transformation

The recent directive by the Central Drugs Standard Control Organisation (CDSCO), operationalized through different state-level Drugs Control Administration circulars, marks a watershed moment in the trajectory of public health safety in India. By mandating the prominent display of Quick Response (QR) codes and toll-free numbers (1800-180-3024) for Adverse Drug Reaction (ADR) reporting at all retail and wholesale pharmacy outlets, the regulator has signalled a decisive shift from a passive, professional-centric surveillance model to an active, consumer-driven ecosystem. This initiative, grounded in the broader Pharmacovigilance Programme of India (PvPI), attempts to democratize drug safety surveillance by placing the reporting mechanism directly into the hands of the consumer, thereby addressing the persistent challenge of under-reporting that has historically plagued the Indian pharmacovigilance landscape. However, the transition from a "press release" to a functional "monitoring and redressal mechanism" exposes profound infrastructural and systemic gaps.

The current operational landscape is characterized by a dichotomy: a regulatory intent focused on "**unified compliance**" and "**public empowerment**", juxtaposed against a fragmented healthcare ecosystem grappling with technological obsolescence, data silos, and a lack of integrated redressal frameworks for patients harmed by marketed drugs.

The scale of data anticipated from direct-to-consumer reporting—characterized by high volume, velocity, and variety (vernacular audio, images, unstructured text)—far exceeds the processing capacity of traditional manual workflows currently employed by the Indian Pharmacopoeia Commission (IPC).

However, this transition from "press release" to a functional "redressal mechanism" exposes significant gaps in technological infrastructure and legal frameworks. Addressing these necessitates a radical architectural overhaul, integrating **Generative AI** and a move toward **no-fault compensation** for victims of drug-induced harm.

1. The Regulatory Pulse: Enforcement under the Drugs & Cosmetics Act

The mandate for QR codes is not merely an administrative request; it is a coercive regulatory instrument designed to ensure safety at the "last mile" of drug delivery.

The Evolution of the Pharmacovigilance Programme of India (PvPI): To understand the magnitude of the current mandate, one must situate it within the historical evolution of drug safety in India. The PvPI, formally launched in 2010, was established to safeguard the health of the Indian population by ensuring that the benefits of medicines outweigh the risks. Initially, the program relied heavily on a limited network of Adverse Drug Reaction Monitoring Centres (AMCs), primarily located in government medical colleges. The flow of information was hierarchical and slow – clinicians identified an ADR, documented it on paper or basic digital forms, and submitted it to the National Coordination Centre (NCC) at the IPC, Ghaziabad.

Legal Basis for Compliance: Under the **Drugs and Cosmetics Act, 1940**, and **Rules, 1945**, licensing authorities have the power to ensure that drugs marketed are safe and effective. Failure to comply with license conditions, including new safety display mandates, can

(Continued on page 24)

Strategic Implementation of QR Codes in ADR: A Mandate for Next-Generation Pharmacovigilance in India

2

(Continued from page 23)

lead to the suspension or cancellation of licenses.

Mandatory Pharmacovigilance: Since December 2023, the establishment of a pharmacovigilance system is mandatory for all manufacturers under **Revised Schedule M** (Clause 6.11). Non-compliance is punishable under Section 18 read with Section 27 of the Act.

Bridging the "Iceberg Phenomenon": For over a decade, the system struggled with significant under-reporting. This under-reporting is termed the "**iceberg phenomenon**," where only the most visible, severe or unusual cases are reported, while the vast majority of drug-induced harms remain submerged in clinical silence. Thereby historically, Indian pharmacovigilance suffered from massive under-reporting. The QR code initiative aims to bypass professional bottlenecks—such as a doctor's fear of liability—by placing the reporting trigger directly in the hands of the consumer.

2. The Infrastructure of Intelligence: Generative AI for Mass Reporting

The "present scenario" of mass public reporting requires a cognitive, adaptive, and scalable infrastructure. Manual processing by the **Indian Pharmacopoeia Commission (IPC)** cannot handle the anticipated "**data tsunami**".

Multimodal Data Ingestion: AI must process high-velocity data including vernacular audio clips, photos of rashes, and handwritten prescriptions.

Intelligent Intake Layer: Utilizing models like OpenAI's Whisper or Google's Universal Speech Model, the system can transcribe and translate 22 scheduled Indian languages into standardized English for **MedDRA** coding.

Automated Case Processing: Generative AI reduces case narrative writing from 30 minutes to 30 seconds. Large Language Models (LLMs) excel at mapping layperson terms (e.g., "walking on cotton wool") to medical terms like "Paraesthesia".

3. Closing the "Redressal" Void: Legal and Financial Evolution

A critical ambiguity exists in the term "**redressal**". While the **New Drugs and Clinical Trials Rules, 2019**, provide a robust compensation framework for trial subjects, no such automatic protection exists for the general public using marketed drugs.

The Failure of the Tort System: Proving "negligence" in a civil court for an idiosyncratic ADR is nearly impossible for an average citizen.

The Architecture of Intelligence: The user correctly surmises that the "present scenario" of mass public reporting "needs lots of Ai generative infrastructure." The volume of data generated by 1.4 billion potential reporters cannot be managed by human pharmacovigilance associates alone. The infrastructure must be cognitive, adaptive, and scalable.

No-Fault Compensation (NFC): India must move toward NFC model where patients receive compensation from a central fund for severe, scientifically linked drug injuries, regardless of manufacturer "**fault**".

Safety Cess: This fund could be financed by a microscopic levy (e.g., 0.05%) on pharmaceutical turnover, effectively socializing the risk of drug consumption.

4. Digital Convergence: ABDM and the Unified Health Interface

(Continued on page 25)

Strategic Implementation of QR Codes in ADR: A Mandate for Next-Generation Pharmacovigilance in India

3

(Continued from page 24)

The **Ayushman Bharat Digital Mission (ABDM)** provides the backbone for an interoperable safety ecosystem.

ABHA Integration: Linking reports to a patient's unique health ID (ABHA) allows regulators to access longitudinal health records with consent, providing vital context for causality assessment.

Health Facility Registry (HFR) & Health Professional Registry (HPR): Every doctor and hospital is registered in ABDM. The PvPI system can validate the credentials of a reporting doctor instantly against the HPR, filtering out fake reports.

UHI – The "UPI Moment" for Safety: Rather than a dedicated app, ADR reporting should be a **UHI-enabled service** integrated into popular apps like Tata 1mg or Apollo 24/7.

Community Pharmacists: With the new QR code mandate, the **pharmacist** becomes the first point of contact. Training modules must be rolled out to train pharmacists on how to assist illiterate patients in scanning the code and recording a voice report.

Accreditation: For hospitals, NABH (National Accreditation Board for Hospitals) should make "Automated ADR Reporting Integration" a mandatory standard for accreditation. This forces hospital management to invest in the necessary IT integration.

5. The Need of the Hour: Strategic Roadmap

To transform the CDSCO's mandate into a tangible reality, the following phased interventions may be required:

Phase 1 (Foundations): Issue a **"Safe Harbor"** notification ensuring that ADR reporting is a protected public health activity and cannot be used as an admission of negligence in medical malpractice suits.

Phase 2 (Integration): Roll out the GenAI Intake Layer and integrate with ABDM for user authentication.

Phase 3 (Redressal): Launch a pilot **National Vaccine and Drug Injury Compensation Fund** to rapidly adjudicate claims of drug injury.

Conclusion

The CDSCO's press release and the accompanying state circulars represent a bold ambition: to transform every pharmacy in India into a listening post for patient safety. However, ambition without infrastructure is hallucination. The "present scenario" is fragile; the flood of data from a mobilized public will collapse the existing manual systems unless immediate action is taken. What is needed is not just "**monitoring**," but an ecosystem of **Intelligent Trust.**

By leveraging the **Drugs and Cosmetics Act** and constructing a robust AI-driven digital backbone, India can leapfrog into a global leadership position in patient-centric drug safety.

The National Medical Commission (**NMC**) should link ADR reporting to the mandatory Continuing Medical Education (**CME**) points required for license renewal.

This requires the construction of a Generative AI infrastructure that can listen to the nation's diverse voices, an interoperable digital backbone (ABDM) that connects disparate agencies, and a legal framework that offers true redressal to those harmed. By executing the roadmap outlined above, India can leapfrog from a legacy PV model to a global leadership position in AI-driven, patient-centric drug safety. The technology exists; the imperative is execution.

——

Revised Schedule M: Strengthening India's Drug Regulatory Oversight

1

H L Ravat
Joint Commissioner
FDCA Gujarat

From Compliance to Quality Governance: A Regulatory Reset

The notification of the Revised Schedule M under the Drugs and Cosmetics Rules, 1945 on 28 December 2023 marks a decisive shift in India's pharmaceutical regulatory framework. More than a procedural amendment, the revised Schedule M represents a systemic reform in how drug regulators evaluate, enforce, and sustain manufacturing quality across the country.

Good Manufacturing Practices (GMP), first introduced into Schedule M in 1988 and last amended in 2005, had largely remained infrastructure- and documentation-centric. Over the years, global regulatory expectations evolved significantly, necessitating a modern, risk-based, and system-oriented approach. The revised Schedule M responds directly to this regulatory need.

Why the Revision Matters to Regulators

India's global role as the *"pharmacy of the world"* places Indian drug regulators under constant international scrutiny. Recent global incidents—such as paediatric fatalities linked to contaminated medicines exported from India and quality failures detected in overseas markets—have reinforced the need for preventive regulatory control rather than reactive enforcement.

The revised Schedule M aligns Indian GMP with international benchmarks, particularly those advocated by the World Health Organization, enabling regulators to demonstrate credibility, consistency, and scientific oversight in GMP enforcement.

Key Regulatory Shifts Introduced

The revised Schedule M fundamentally redefines the inspection and enforcement paradigm:

• Pharmaceutical Quality System (PQS): Inspectors now assess management accountability, quality objectives, and continuous improvement mechanisms, not merely SOP availability.

• Quality Risk Management (QRM): Risk-based thinking becomes central to inspections, allowing regulators to evaluate how firms proactively identify and mitigate quality risks.

• Product Quality Review (PQR): Mandatory annual reviews offer regulators a powerful surveillance tool to detect trends, recurring deviations, and systemic weaknesses.

• Validation and Qualification: Lifecycle-based validation shifts regulatory focus from end-product testing to process reliability and predictability.

• Computerised Systems & Data Integrity: Explicit requirements empower inspectors to address data manipulation risks through audit trails, access controls, and electronic record integrity.

Together, these provisions elevate the role of inspectors from checklist verifiers to quality system evaluators.

Phased Implementation: Regulatory Pragmatism

Recognising the scale and diversity of India's pharmaceutical industry—over 10,500 manufacturing units, with nearly 8,500 MSMEs—the revised Schedule M adopts a turnover-based phased implementation:

• Large manufacturers (turnover > ₹250 crore): six months for compliance

• MSMEs (turnover ≤ ₹250 crore): initially twelve months, later extended

While large manufacturers, particularly export-oriented units, transitioned smoothly, MSMEs faced challenges related to infrastructure, capital investment, and skilled manpower.

(Continued on page 27)

Revised Schedule M: Strengthening India's Drug Regulatory Oversight

2

(Continued from page 26)

In response to industry representations, the Central Government issued a notification on 04 January 2025, extending the MSME compliance deadline to 31 December 2025, subject to mandatory gap analysis and a time-bound compliance plan. For regulators, this conditional extension ensures flexibility without dilution of standards.

Role of CDSCO and State Regulators

The Central Drugs Standard Control Organisation has taken a lead role in operationalising the revised Schedule M through:

• National-level guidance and coordination

• Training and sensitisation of inspectors

• Promoting consistency in GMP interpretation across states

State Drug Control Departments are progressively transitioning to risk-based, system-focused inspections, requiring continuous skill upgradation and harmonisation of enforcement practices.

Capacity Building and Financial Enablement

Effective enforcement requires both regulatory capability and industry preparedness. The Department of Pharmaceuticals has merged APICF, PTUAS, and PPDS into the Strengthening of Pharmaceuticals Industry (SPI) scheme. This initiative provides reimbursement-based financial assistance for facility upgradation, supporting MSMEs in achieving revised Schedule M and WHO -GMP compliance.

From a regulatory standpoint, such schemes act as compliance enablers, reducing resistance to enforcement and improving long-term outcomes.

What Inspectors Should Focus On

Under the revised Schedule M, regulatory inspections should prioritise:

• Effectiveness of PQS and QRM, not mere documentation

• Trend analysis through PQR and complaint data

• Validation status of critical processes and utilities

• Data integrity risks in computerised systems

• Management involvement in quality decision-making

Persistent or willful non-compliance continues to warrant stringent regulatory action, including show-cause notices, licence suspension, or manufacturing restrictions.

The revised Schedule M is a governance reform, not just a technical upgrade. Its success will depend on:

• Inspector competence and consistency

• Balanced enforcement with public health focus

• Supportive transition for MSMEs

• Continuous coordination between central and state regulators

Implemented effectively, the revised Schedule M will strengthen public health protection, enhance global confidence in Indian regulatory oversight, and reinforce India's position as a reliable supplier of quality medicines.

"Quality cannot be inspected into a product—it must be built into systems. Revised Schedule M gives regulators the tools to ensure exactly that."

———

DCOIWA'S Advisory Committee 2025-2028

DCOIWA's ADVISORY COMMITTEE FOR THE PERIOD 2025-28

Chairman
Narendra Kumar Ahooja
(Haryana)
Mob: 9878748899

Co-Chairman
K.R. Chawla
(Delhi)
Mob: 9811262327

Member
D. Hanumantha Rao
(Telangana)
Mob: 9440897896

Member
Dr.B.R.Jagashetty
(Karnataka)
Mob: 9449818892

Member
A. Manikandan IAS
(Uttar Pradesh)
Mob: 94440 61429

Member
Dr. Pradeep Mattu
(Punjab)
Mob: 9815872275

Member
Omprakash Sadhwani
(Maharashtra)
Mob: 98673 25648

Member
V. R. Shah
(Gujarat)
Mob: 9825061450

ADVISORY

SLA list as on 20-01-2026

SLA's / DC's

List as on 20.01.2026

1

Sr. No.	State Name	Name of Drugs Controllers/SDC	Contact Details	Email Address	Address
1	Andhra Pradesh	 M. Pandu Ranga Prasad (Director & SLA)	94901 53336	tappal-dgdca@ap.gov.in	Director General, Drugs Control Administration, Siddartha medical college campus, Vijayawada - 520008, Andhra Pradesh
2	Arunachal Pradesh	 Mr. Gebomb Tayeng (Drugs Controller & SLA)	9436055664	drugscontrolap@gmail.com gtayeng234@gmail.com	Drugs Control Administration, Room no. 150, Second Floor, Directorate of Health Services Naharlagun -791110, Arunachal Pradesh
3	Assam	 Mr. Biswajit Talukdar (Drugs Controller & SLA)	7086084833	drugscontrol.assam@gmail.com	Directorate of Health Services, 2nd Floor hengrabari, Kamrup metro, Gowahati-781 036, Assam.
4	Bihar	 Mr. Nityanand Kishloya (Drugs Controller)	91228 24144	sdcbihar.bih@gmail.com	Directorate of Drugs Control Administration, 6th Floor, Swasthya Bhawan, Sheikhpura, Patna, Bihar. 800014.
5	Chattisgarh	 Mr Beni Ram Sahu SLA & Controling authority	93034 31563	controllerraipur@gmail.com	Office of the Controller, Food and Drugs Admn., Block B, Fourth Floor, Indrawati Bhawan, Nava Raipur, Chhattisgarh 492002.
6	Goa	 Ms. Shweta Savindra Dessai (Director & SLA)	9850600390	off-dfda.goa@nic.in shweta.dessai@rediffmail.com	Director of Food and Drugs Administration, Dhanwantari, Opp.Shrine of the Holy cross, Bombolim, GOA-403202
7	Gujarat	 Mr. H. L. Ravat (Licensing & Controlling Authority)	9099977135	comfdca@gujarat.gov.in	Office of the Commissioner FDCA, Dr Jivaraj Mehta Bhavan, First floor , Old Sachivalaya, Gandhinagar, Gujarat - 382010
8	Haryana	 Mr. Lalit Kr. Goel (Drugs Controller & SLA)	7056702999	haryanafda@gmail.com	Food and Drugs Administration, SCO-94, Sector-5, Panchkula, Haryana - 134 109
9	Himachal Pradesh	 Mr. Manish Kapoor (Drugs Controller & SLA)	94180 81270	sdc4hp@gmail.com	Office of State Drugs Controller, HIMUDA Building, 2nd Floor, Sai Road, Baddi, District-Solan, Himachal Pradesh - 173205.
10	Jharkhand	 Mrs. Ritu Sahay (Drugs Controller & SLA)	7564903403	directoratedrug. jharkhand@gmail.com	Drugs Control Directorate, RCH Campus, Namkum, RANCHI - 834010 JARKHAND.

SLA list as on 20-01-2026

11	Karnataka	 Dr. S. Umesh (Addl. Drugs Controller)	94480 54321	dckarnataka @gmail.com	O/O Commissioner, FDA, Palace Road, Bengaluru -560001, Karnataka.
12	Kerala	 Dr. Sujith Kumar K (Drugs Controller & SLA)	9447629012	dckerala@gmail.com	Office of Drug Controller, Red Cross Road, Vanchiyoor, PO: Thiruvananthapuram-695035 Kerala
13.	Madhya Pradesh	 Mr. Rajesh Jinwal SLA  Mr. Dharmesh Bigonia Incharge Officer	9893472170 9893280364	fdampbhopal@gmail.com	Controller, Food and Drugs Administration, Idgah Hills, Bhopal, Madhya Pradesh-462001.
14.	Maharastra	 Mr. V. T. Jadhav Joint Commissioner (HQ) / Controlling Authority	9421072851	jchq.fda-mah@nic.in	Food and Drugs Administration, 341, Bandra Kurla Complex, Kala Nagar, Bandra East, Mumbai-400051, Maharashtra.
15.	Manipur	 Mr. Seram Baleshwar Singh (Drug Controller)	9436846354	serambaleshwar @gmail.com	Drug Controll Administration, Govt. Of Manipur, R&D Wing Complex, Lamphel Pat, Imphal West District, Manipur - 795001.
16.	Megalaya	 Mrs. Arulia Rela Kharwanlang (Drugs Controller & SLA)	9774077248	megh@gmai.com	O/o The Drugs Controller, Directorate Of Health Services (MI) Pasteur, Hills: Lawmali, Shillong, Meghalaya - 793001
17.	Mizoram	 Mr. F. Lalliantluanga (Controlling & Licensing Authority)	70050 84957	mizoramfda2@gmail.com	Food and Drug Administration, Directorate wing, Director of Health Services, Dinthar, Aizwal, Mizoram - 796 009
18.	Nagaland	 Mr. Martemjen Longkumer (Drugs Controller)	94024 89080	nagalanddca@gmail.com	Drugs Control Administration, Directorate of Health and Family welfare, Kohima 797001, Nagaland
19.	Odisha	 Ms. Mamina Patnaik (Drugs Controller)	9437013646	drugscontrolorissa @gmail.com	Directorate of Drugs Control, Press Chhak, Near New Government Colony, Gajapati Nagar, P. O.- Macheswar Railway Colony, Bhubaneswar-751017, Odisha.

SLA list as on 20-01-2026

20.	Punjab	 Mr. Sanjiv Kumar (Joint Commissioner & SLA)	9501005278	punjabdrugscontrolorg@gmail.com	Commissionerate of Food and Drugs Administration (Drugs Wing), Government Dispensary Complex,Mohali Stadium Road,Phase 9,Mohali,Dist Sahibzada Ajit Singh Nagar, Punjab - 160 062
21.	Rajasthan	 Mr. Ajay Phatak (Drug Controller & SLA)	9414355650	commisionerfs&dc@rajasthan.gov.in drugcontroller1.mh@rajasthan.gov.in drugcontroller2.mh@rajasthan.gov.in	O/o Commissoner, Food and Drugs Administration, Swasthya Bhawan, Tilak Marg, Jaipur, Rajasthan – 302 005
22.	Sikkim	 Mr. B. Iyangain Martin Targain (Director & SLA)	94234103376	sikkimdrugscontrol@gmail.com	Dept. of Health & FW, Gangtok, SIKKIM - 737101
23.	Tamil Nadu	 Mr. Gurubharathi Joint Director cum Controlling & Licensing authorty  Mr. Nanda Kumar (Dy, Director of Drugs Control & LA	9994773938 9994153831	tndcad@gmail.com	The Directorate of Drugs Control Administration, 359, Anna Salai, Teynampet, DMS Campus, Chennai - 600006, Tamilnadu.
24.	Telangana	 Mr. G. Ramdhan (Joint Director & SLA)	96669 84242	dcatelangana@gmail.com	Drugs Control Administration, 79, Vengal Rao Nagar Rd, Mothi Nagar, Vengal Rao Nagar, Sanjeeva Reddy Nagar, Hyderabad, Telangana 500038
25.	Tripura	 Mr. Subrata Das (Drug Controller & SLA)	70054 45983	drugscontroltripura@gmail.com	O/o The Deputy Drugs Controller, Aushadhi Niyantran Bhavan, Pandit Nehru Office Complex, Gurkhabasti, Kunjaban (P.O) - 799006 Agartala (Tripura)
26.	Uttar Pradesh	 Mr. S M Gupta (Drug Controller & SLA)	9415082474	upfdadrug@gmail.com	Food Safety and Drugs Administration, Sector-C, Aliganj, Lucknow-226024 Uttar Pradesh
27.	Uttarakhand	 Mr. Tajber Singh (Drugs Controller & SLA)	7579210856	drugcontroluk@gmail.Com	O/o Commissioner Food safety and Drugs Administration Uttarakhand, Dan da Lakhond, Near IT Park, Sahastrdhara road, Dehradun - 248 001 Uttarakhand.
28.	West Bengal	 Mr. Rathindranath Roy (SLA)	9433116050	tellddcwb@gmail.com	Directorate of Drugs Control, Government of West Bengal, 142, A. J. C. Bose Road (4th to 9th Floor), Kolkata -700014 West Bengal

SLA list as on 20-01-2026

ALL UTS LICENSING AUTHOURITIS IN INDIA

4

Sr. No.	State Name	Name of Drugs Controllers/SDC	Contact Details	Email Address	Address
1.	Andaman and Nicobar	Dr. Mrs. Munni Singania (Dy. Commissioner & SLA)	9434280133	dirdhs.and@nic.in	Department of Health Services, Andaman and Nicobar, PORT BLAIR - 744104
2.	Chandigarh	 Dr. Suman Singh (Dy. Commissioner & SLA)	0172-2700255	drugscontroller chandigarh@gmail.com	Directorate Health Services, Drugs Controller cum L.A. Administrative Building GMSH Sector 16, Chandigarh - 160 015
3.	Dadra and Nagar, Haveli & Daman & Diu	 Dr. Dharmesh Agrawal (DC & SLA)	9824500354	dharmeshdla@gmail.com	Directorate of Medical and Health Services, Primary Health centre, Fort Area, Moti Daman - 396220, Daman (U.T.)
4.	Puducherry	 Dr. E. Anandakirouchenane (DC & SLA)	9443957680 0413 -2353647	ddc.pon@nic.in	1st Floor, Dept. of Drugs control Indira Nagar, Gorimedu Puducherry- 605006
5.	Delhi	 Mr. Rajeev Bhargav (Drugs Controller)	98181 24729	dirdcd@nic.in	Controlling & Licensing Authority Drugs Control Department, Govt. of NCT of Delhi, F17, Karkordooma, Delhi - 110032
6.	Jammu and Kashmir (J & K)	 Mr. Rajesh Kumar (Drugs Controller)	94191 50046	controllerdrugs foodjk@gmail.com	Office of the State Drugs Controller, Drugs & Food Control Organization, J&K 1st Floor, Combined Food & Drug Laboratory, Patoli Mangotrian, Jammu - 180 001(J & K)
7.	Lakshwadweep	Mr. Bharani (SLA)	8300011196	bufferhelthdhs@gmail.com	Directorate of Health Services U.T. of Lakshadweep, Kavaratti Island - 682555
8.	Ladakh	 Mrs. Nasrina Bano (SLA)	9906948166	controllerdfcoladakh @gmail.com	Drugs and Food control oraganization, Near RTO Office , Dambuchan-Agling NEH-194101, UT Ladakh

Send your news and articles to:
dcoiwanewsletter@gmail.com

DCOIWA Webinar Series-10

Drug-Drug interactions: A critical & Regulatory Perspective

Appointment and Administrative Reorganization in Gujarat Drug Control Administration

Dated: 31/01/2026

The State Government of Gujarat is pleased to announce significant developments within the Drug Control Administration, aimed at further strengthening the regulation and enforcement of drug laws across the state.

Appointment of New Drugs Inspectors

In a move to enhance public health and streamline regulatory compliance, the Government has appointed thirty (30) new Drugs Inspectors. These appointments are expected to bolster the inspection and surveillance of pharmaceutical manufacturing, distribution, and retail outlets, ensuring the continued safety and efficacy of medicines available to the public.

Promotions of Assistant Commissioners

Furthermore, in recognition of their exemplary service and dedication, four (4) Assistant Commissioners have been promoted to the rank of Deputy Commissioner. This elevation will empower them with greater responsibilities and enable stronger leadership within the regulatory framework.

Transfers within the Drug Control Administration

In addition to the above, the State Government has also undertaken administrative transfers involving the remaining Drugs Inspectors, Assistant Commissioners, and Senior Drugs Inspectors. These transfers are part of a routine exercise to optimise administrative efficiency, encourage the sharing of best practices, and ensure effective governance throughout the state.

The Government remains committed to upholding the highest standards of pharmaceutical regulation, safeguarding public health, and supporting the professional growth of its officers. All newly appointed and transferred officers are expected to assume their respective roles with immediate effect.

Source: Dr. Arvind. H. Zala

FDA Haryana

Hisar

30-01-2026

Raid- Drugs Act, NDPS Act and MTP Act.

Team:

- Ajay Kumar DCO
- Dr. Anamika Bishnoi, PNDT In-charge, Hisar.
- Dr. Promil Garg Hissar.

Place: Shri Balaji Clinic, Azad Nagar, Hisar.

During the operation, a decoy customer was sent to the clinic for the purpose of sex determination.

As soon as the decoy customer handed over cash to a person at the clinic, the team immediately raided the premises.

During the raid, a lady was found lying on a bed, and a person was standing beside her, operating a machine on her abdomen.

Three persons, namely Dr. Anantram, Dr. Surajmal, and Smt. Priyanka, were found present at the spot.

During the inspection, the team recovered and seized one computer-like machine with probe, MTP kits, allopathic medicines, and NDPS drugs from the premises.

The NDPS drugs were handed over to the police for necessary action under the NDPS Act.

Accordingly, an FIR was registered for violations of relevant provisions of law.

Source: Ajay Kumar, FDA Haryana

FDA Haryana

Sirsa
17.01.26

Team members;

- Suneel Kumar, DCO
- Police Staff Sirsa

Drugs control officer, Sirsa-II, Mr. Suneel Kumar along with Police official of PP,Chautala,Mandi Dabwali

Place: Village- Chautala

Purpose:

To investigate a secret complaint regarding illegal sale stocking and distribution of dual use prescription drugs.

Arshdeep singh VPO-Asha Khera. Siezed 220 Tapentadol HCl tablets and 255 Pregabalin IP 300 mg capsules.

He did not show any relevant document at the spot.

So, 02 types of allopathic drugs were seized by sampling vide form-17.

Further action will be taken as per law under Drugs Act.

Source: Suneel Kumar, FDA Haryana

Sirsa
17.01.26

Team members;

- Keshav Vashistha DCO
- ABVT Staff, Sirsa

Place : Near Kanda Colony, Gali No. 03, Sirsa

Purpose:

To investigate a secret complaint regarding illegal sale stocking and distribution of dual use prescription drugs

Mr. Kapil and Mr. Veeru, R/o Near Kanda Colony, Gali No. 03, Sirsa found present.

Seized 510 Tapentadol HCl tablets and 1620 Pregabalin capsules.

He did not show any relevant document at the spot.

So, 02 types of allopathic drugs were seized by sampling vide form-17.

Further action will be taken as per law under Drugs Act.

Source: Keshav Vashishth, FDA Haryana

FDA Haryana

Gurgaon
15-01-2026

Team members:

- Amandeep Chauhan., DCO
- Dr. Suresh Kumar. DCO
- Mukesh Kumar, DCO

Place: M/s Lenscare Vision Pvt. Ltd. Situated at Ground Floor, Flat No. G-156, Palam Vihar Extension, Gurugram.

Purpose:

To investigate a secret complaint that sale of medical devices is being done there without any valid license and import licenses.

Raju Kumar was found present at the spot.

He did not show any relevant document at the spot.

So, 20 types of medical devices of worth Rs. 447241/- was seized on form MD-35.

Further action will be taken as per law under Drugs Act.

Source: Amandeep Chauhan DCO, FDA Haryana

Karnal
12.01.2026

Team members:

- Ritu Mehla
- Police person's of Karnal.

Allopathic drugs were seized from the residential premises of Mr. Mukesh Kumar, located near Dada Khera, Mallu Patti, VPO Salwan, District Karnal.

Mr. Mukesh Kumar failed to produce any valid drug licence .

(80 tablets of Pregabalin 300 mg and one MTP kit) NDPS Act were also seized separately by the police, including Tramadol and Alprazolam.

FIR has been registered under the NDPS Act against Mr. Mukesh Kumar at Police Station Assandh.

Further, on the disclosure made by Mr. Mukesh Kumar, it was revealed that he had been selling drugs to M/s Anil Medical Hall, VPO Salwan.

During investigation, the proprietor of M/s Anil Medical Hall confessed that he had purchased five injections of Tramadol and one MTP kit from Mr. Mukesh Kumar on 23.12.2025 without any purchase bill and had illegally sold the same without issuing any cash memo.

Consequently, the shop premises of M/s Anil Medical Hall have been sealed.

Source: Ritu Mehla DCO, FDA Haryana

FDA Haryana

Karnal
12.01.2026

Team members:

- Ritu Mehla
- Police person's of Karnal.

Allopathic drugs were seized from the residential premises of Mr. Mukesh Kumar, located near Dada Khera, Mallu Patti, VPO Salwan, District Karnal.

Mr. Mukesh Kumar failed to produce any valid drug licence .

(80 tablets of Pregabalin 300 mg and one MTP kit) NDPS Act were also seized separately by the police, including Tramadol and Alprazolam.

FIR has been registered under the NDPS Act against Mr. Mukesh Kumar at Police Station Assandh.

Further, on the disclosure made by Mr. Mukesh Kumar, it was revealed that he had been selling drugs to M/s Anil Medical Hall, VPO Salwan.

During investigation, the proprietor of M/s Anil Medical Hall confessed that he had purchased five injections of Tramadol and one MTP kit from Mr. Mukesh Kumar on 23.12.2025 without any purchase bill and had illegally sold the same without issuing any cash memo.

Consequently, the shop premises of M/s Anil Medical Hall have been sealed.

Source: Ritu Mehla DCO, FDA Haryana

Sirsa
12.1.26

Team members:

- Keshav Vashishth, DCO
- Police persons, Sirsa

The team checked shop of M/s Shree Krishna Medicos, Village Khuiyan Malkan, Teh Dabwali Sirsa .

Violating the conditions of license under Drugs and cosmetics act and rules were detected.

In contituation of the same the team has also searched the residential premises of Mr. Om Parkash (Prop. cum R.P.) of the firm, situated adjacent to the firm in presence of Mr. Om Parkash.

On searching the house the team recoverd Two strips of MTP KIT.

Seized vide Form-16 as per D&C Act.

To stop the furtherance of offence the said firm was sealed.

Source: Keshav Vashishth, FDA Haryana

Send your news and articles to:
dcoiwanewsletter@gmail.com

FDA Haryana

Ambala

11-01-2026

Under the able guidance of Sh. Lalit Kumar Goel, State Drugs Controller, FDA Haryana, the members of the Ambala Retail Chemist Association will visit the Vulture Breeding Centre at Pinjore.

The purpose of this visit is to understand the complete life cycle of vultures, from egg to fully grown bird, and how they are released into the open sky to support environmental protection. Vultures are natural scavengers and play a vital role in keeping our environment clean.

During the visit, the Association will also discuss four veterinary drugs that have been banned.

This initiative aims to educate and motivate every chemist about the importance of not selling these harmful veterinary medicines.

Through this awareness drive, the Chemist Association will take the lead in this initiative under the mission name “Save Vultures.”

Source: Lalit Kr Goel, FDA Haryana

FDA Haryana

Sirsa

09-01-2026

Suneel Kumar, DCO, along with Police officials, conducted a raid at M/s Sudhir Medicose, situated Opposite Devi Lal Park, GT Road, Mandi Dabwali, District Sirsa.

During inspection, Kapil Bansal, Proprietor of the firm, was found stocking the following drugs:

Tapentadol Tablets – 200

Pregabalin Capsules – 64

Zopiclone Tablets – 45

No purchase or sale records were produced or shown during the inspection.

Subsequently, the residential premises of the proprietor, located at House No. 15, Ward No. 2, Mandi Dabwali, were also raided for further investigation.

A huge quantity of allopathic drugs was recovered from the residential premises.

A total of 14 types of allopathic drugs were recovered, including:

Tapentadol Tablets 10,950

Pregabalin Cap 22,870

Zopiclone Tablets – 70,770

Gabapentin Capsules IP 300 mg – 780 Capsules

Pregabalin 75 mg + Methylcobalamin Capsules – 120 Capsules

All 14 types of allopathic drugs were seized under Form-16.

The shop premises were sealed to prevent further continuation of the offence.

The raid operation continued till late night up to 2:00 AM.

Source: Suneel Kumar DCO, FDA Haryana

FDA Haryana in news

हरियाणा में फार्मास्युटिकल उद्योग के अवसर और विकास पर सेमिनार का आयोजन

करनाल में फार्मा पार्क की स्थापना करने व सूक्ष्म, लघु इकाइयों को सहयोग देने की मांग

भास्कर न्यूज | करनाल

हरियाणा फार्मास्युटिकल मैन्युफैक्चरर्स एसोसिएशन की ओर से होटल द विवान में हरियाणा में फार्मास्युटिकल उद्योग के अवसर और विकास विषय पर एक दिवसीय सेमिनार का आयोजन किया गया। इस दौरान हरियाणा के विभिन्न जिलों से आए 125 से अधिक औषधि निर्माताओं ने भाग लेकर उद्योग से जुड़े महत्वपूर्ण विषयों पर विचार-विमर्श किया।

मुख्य अतिथि के तौर पर विधायक जगमोहन आनंद ने एचपीएमए के प्रयासों की सराहना करते हुए उद्योग को हरसंभव सहयोग देने का आश्वासन दिया। उन्होंने कहा कि सभी मांगों को राज्य सरकार के समक्ष रखा जाएगा। उन्होंने कहा कि संशोधित शेड्यूल-एम में विस्तार की मांग को लेकर केंद्रीय मंत्री मनोहर लाल के माध्यम से केंद्र सरकार तक पहुंचाया जाएगा। साथ ही, करनाल में फार्मा पार्क की स्थापना के विषय को भी गंभीरता से उठाने का भरोसा दिलाया। इससे पहले कार्यक्रम की शुरुआत एचपीएमए के अध्यक्ष आरएल शर्मा के स्वागत भाषण से हुई। उन्होंने फार्मास्युटिकल उद्योग को प्रदेश की अर्थव्यवस्था का अहम स्तंभ बताते हुए इसके सतत् विकास पर बल दिया। इसके बाद महासचिव विकास परूथी ने पिछले दो वर्षों में एसोसिएशन की उपलब्धियों की जानकारी साझा की।

करनाल. सेमिनार में विधायक जगमोहन आनंद का स्वागत करते हुए।

उन्होंने उद्योग के समक्ष आ रही व्यावहारिक समस्याओं को रखते हुए सरकार और नियामक अधिकारियों के समक्ष प्रमुख मांगें भी रखीं।

सेमिनार में एमएसएमई इकाइयों के लिए संशोधित शेड्यूल-एम के क्रियान्वयन में कम से कम दो वर्ष का विस्तार, जीएमपी एवं जीएलपी प्रमाण पत्रों का निर्गमन जोनल कार्यालय से किए जाने, करनाल में फार्मा पार्क की शीघ्र स्थापना, सूक्ष्म एवं लघु इकाइयों को तकनीकी सहयोग उपलब्ध कराने तथा ओएनडीएलएस पोर्टल पूर्ण रूप से कार्यशील होने तक हाइब्रिड मोड जारी रखने जैसी मांगें प्रमुख रूप से उठाई गईं। इस अवसर पर राज्य औषधि नियंत्रक हरियाणा ललित गोयल, उप औषधि नियंत्रक (भारत) डॉ. अजय सचान, तथा उप राज्य औषधि नियंत्रक रिपन मेहता, राजीव गर्ग मौजूद रहे।

नशा मुक्ति केंद्र के मेडिकल स्टोर में मिलीं अनियमितताएं, सील किया

दवाइयों के रिकॉर्ड में हेराफेरी मिलने पर ड्रग विभाग की कार्रवाई

डबवाली। बठिंडा रोड स्थित मानसिक रोग और नशा मुक्ति केंद्र में स्थित मेडिकल स्टोर एमएस बालाजी ट्रेडर्स पर वीरवार को छापा मारा। इस दौरान दवाइयों के रिकॉर्ड में अनियमितताएं मिलने पर स्टोर को सील कर दिया गया।

ड्रग कंट्रोलर केशव विशिष्ट ने बताया कि टीम ने मेडिकल स्टोर में दवाइयों, उनके खरीद, भंडारण और वितरण के रिकॉर्ड की गहन जांच की। जांच में सामने आया कि दवाइयों के रिकॉर्ड में कई खामियां थीं। कुछ दवाइयों का स्पष्ट लेखा-जोखा रिकॉर्ड में दर्ज नहीं था, जबकि नियंत्रित और प्रतिबंधित दवाओं से संबंधित रिकॉर्ड में भी गंभीर अनियमितताएं पाई गईं। विभाग ने मेडिकल स्टोर से सभी संबंधित रिकॉर्ड जब्त कर लिया है।

सिरसा से आए ड्रग कंट्रोलर केशव विशिष्ट ने बताया कि विभाग को शिकायत प्राप्त हुई थी कि नशा मुक्ति केंद्र से जुड़े इस मेडिकल स्टोर में दवाइयों के रिकॉर्ड में हेराफेरी की जा रही है और निर्धारित नियमों का पालन नहीं हो रहा। शिकायत की सत्यता की जांच के लिए औचक निरीक्षण किया गया, जिसमें शिकायत सही पाई गई। संवाद

टाडालाफिल मामले में आयुष लाइसेंसिंग अथॉरिटी दिलीप मिश्रा की सख्त कार्रवाई, फर्म का लाइसेंस अस्थाई रूप से निलंबित

▶▶आयुर्वेदिक दवा में मिला था एलोपैथिक टाडालाफिल, केंद्रीय ड्रग विभाग ने किया था एनएसक्यू

▶▶औषधि नियंत्रक ललित गोयल ने भी 22 जनवरी को जारी किया था प्रदेश भर में अलर्ट

अक्षय कुमार शर्मा

पंचकूला / अंबाला : आयुर्वेदिक दवा में एलोपैथिक केमिकल टाडालाफिल पाए जाने के गंभीर मामले में हरियाणा आयुष विभाग की लाइसेंसिंग अथॉरिटी दिलीप मिश्रा ने सख्त कदम उठाते हुए संबंधित आयुर्वेदिक दवा निर्माता के खिलाफ कार्रवाई की है। केंद्र के निर्देशों का अनुपालन न होने के कारण फर्म का आयुष ड्रग लाइसेंस अस्थायी रूप से निलंबित कर दिया गया है।

मामले की शुरूआत उस समय हुई जब केंद्रीय औषधि मानक नियंत्रण संगठन द्वारा की गई जांच में अंबाला की कंपनी में निर्मित एक आयुर्वेदिक दवा एक्सझप्लस गोल्ड के सैंपल को मानक गुणवत्ता के अनुरूप नहीं (ठरद) घोषित किया गया। लैब जांच में सामने आया कि आयुर्वेदिक दावे के साथ बाजार में बेची जा रही इस दवा में एलोपैथिक केमिकल टाडालाफिल मौजूद था, जो कानूनन गंभीर उल्लंघन है।

जैसे ही यह तथ्य सामने आया, केंद्रीय औषधि मानक नियंत्रण संगठन की नोटिफिकेशन के बाद हरियाणा के राज्य औषधि नियंत्रक ललित गोयल ने 22 जनवरी 2026 को पूरे प्रदेश में अलर्ट जारी करते हुए सभी औषधि निरीक्षकों और संबंधित अधिकारियों को सतर्क किया था। अलर्ट में स्पष्ट निर्देश दिए गए कि उक्त दवा की बिक्री पर कड़ी निगरानी रखी जाए और जहां भी यह दवा मिले, वहां तत्काल कार्रवाई की जाए।

केंद्रीय औषधि मानक नियंत्रण संगठन के पत्र अनुसार संबंधित निर्माता को दवा तुरंत बाजार से वापस बुलाने (रिकॉल) और की गई कार्रवाई की रिपोर्ट देने के निर्देश दिए गए थे। हालांकि, निर्धारित समय सीमा के भीतर न तो संतोषजनक जवाब दिया गया और न ही प्रभावी अनुपालन सामने आया। इसी पृष्ठभूमि में 30 जनवरी 2026 को आयुष विभाग के लाइसेंसिंग अधिकारी दिलीप मिश्रा ने इसे ड्रग्स एंड कॉस्मेटिक्स एक्ट, 1940 और ड्रग्स एंड कॉस्मेटिक्स रूल्स, 1945 का उल्लंघन मानते हुए सख्त कार्रवाई की। फर्म का आयुष ड्रग लाइसेंस अस्थायी रूप से सस्पेंड कर दिया गया और कारण बताओ नोटिस जारी किया गया है।

श्री मिश्रा के अनुसार, टाडालाफिल जैसी एलोपैथिक दवा का आयुर्वेदिक उत्पाद में मिलना न केवल जनस्वास्थ्य के लिए खतरा है, बल्कि यह आयुर्वेदिक चिकित्सा पद्धति की विश्वसनीयता पर भी गंभीर प्रश्न खड़े करता है। उन्होंने स्पष्ट किया है कि यदि आगे की जांच में उल्लंघन जारी पाया गया, तो लाइसेंस निरस्तीकरण और कानूनी कार्रवाई से भी इंकार नहीं किया जाएगा।

श्री मिश्रा ने यह भी स्पष्ट किया है कि इस तरह की लापरवाही किसी भी तरह से स्वीकार्य नहीं है और जो भी दवा निर्माता नियमों का उल्लंघन करेगा उसके विरुद्ध सख्त से सख्त कार्रवाही की जाएगी।।

हिसार में अवैध लिंग निर्धारण का भंडाफोड़, बालाजी क्लीनिक पर बड़ी छापेमारी

डिकोय ग्राहक की मदद से पकड़ी गई गैरकानूनी गतिविधि, एनडीपीएस-- एमटीपी-ड्रग्स कानून के तहत प्राथमिकी दर्ज

अक्षय कुमार शर्मा

पंचकूला/हिसार : हरियाणा के हिसार में अवैध लिंग निर्धारण और गैरकानूनी चिकित्सकीय गतिविधियों के विरुद्ध स्वास्थ्य विभाग एवं ड्रग प्रशासन की संयुक्त टीम ने आजाद नगर स्थित श्री बालाजी क्लीनिक पर बड़ी छापेमारी की। यह कार्रवाई ड्रग्स एवं कॉस्मेटिक्स अधिनियम, एनडीपीएस अधिनियम तथा एमटीपी अधिनियम के अंतर्गत की गई। छापेमारी दल में ड्रग कंट्रोल अधिकारी श्री अजय कुमार, पीएनडीटी प्रभारी डॉ. अनामिका विश्नोई एवं डॉ. प्रोमिल गर्ग शामिल रहे। कार्रवाई से पूर्व अवैध लिंग निर्धारण की पुष्टि के लिए एक छद्म (डीकोय) ग्राहक को क्लीनिक भेजा गया। जैसे ही उसने ने क्लीनिक में मौजूद व्यक्ति को नकद राशि सौंपी, टीम ने तत्काल क्लीनिक पर छापा मार दिया। छापे के दौरान एक महिला को बिस्तर पर लेटा पाया गया, जबकि एक व्यक्ति उसके पेट पर मशीन का प्रयोग करता हुआ मिला। मौके पर डॉ. अनंतराम, डॉ. सुरजमल एवं श्रीमती प्रियंका उपस्थित पाए गए।निरीक्षण के दौरान टीम ने कंप्यूटरनुमा अल्ट्रासाउंड मशीन (प्रोब सहित), एमटीपी किट, एलोपैथिक दवाइयाँ तथा एनडीपीएस श्रेणी की दवाइयाँ बरामद कर जब्त कीं। एनडीपीएस से संबंधित दवाइयों को आगे की कानूनी कार्रवाई हेतु पुलिस के हवाले कर दिया गया।मामले में संबंधित धाराओं के अंतर्गत प्राथमिकी दर्ज कर ली गई है तथा आगे की जांच जारी है। इस संबंध में जानकारी देते हुए औषधि नियंत्रक ललित गोयल ने कहा कि अवैध लिंग निर्धारण एवं एनडीपीएस श्रेणी की दवा का दुरुपयोग समाज के लिए गंभीर अपराध है। इस प्रकार की गतिविधियों को किसी भी सूरत में बर्दाश्त नहीं किया जा सकता और इसमें लिप्त दोषियों के खिलाफ कठोरतम कार्रवाई सुनिश्चित है।।

FDA Haryana in news

कॉस्मेटिक उत्पादों की गुणवत्ता की जांच के लिए चला विशेष अभियान

फरीदाबाद में दर्जनों दुकानों पर छापामारी कर लिए सैम्पल

फरीदाबाद, 09 जनवरी, सत्यजय टाईम्स/सुनील अग्रवाल। फरीदाबाद में आज विभिन्न कॉस्मेटिक बेचने वाली दुकानों पर छापा मार कर एफडीए की टीम ने सैम्पल लिए तथा उनको जांच के लिए भेजा गया। इस काम में लगे ड्रग कंट्रोल अधिकारी संदीप गहलान ने बताया कि यह अभियान आज पूरे प्रदेश में चलाया जा रहा है, जिसके तहत फरीदाबाद में भी यह कार्रवाई की जा रही है। मिली जानकारी के अनुसार राज्य औषधि नियंत्रक, हरियाणा ललित गोयल के कार्यालय में कॉस्मेटिक उत्पादों की गुणवत्ता को लेकर लगातार शिकायतें प्राप्त हो रही थीं। उक्त शिकायतों के दृष्टिगत दिनांक वीरवार को पूरे हरियाणा राज्य में कॉस्मेटिक उत्पादों के सैंपल लेने हेतु एक विशेष अभियान (स्पेशल ड्राइव) चलाया गया।

इस अभियान के अंतर्गत सभी जिलों में रिटेलर्स, होलसेलर्स, मॉल्स एवं जनरल स्टोर्स आदि से कॉस्मेटिक उत्पादों के नमूने लिए गए, ताकि उनकी गुणवत्ता की जांच की जा सके और यह सुनिश्चित किया जा सके कि वे ड्रग्स एंड कॉस्मेटिक्स अधिनियम एवं नियमों के अनुरूप हैं।

फरीदाबाद में संदीप गहलैन, ड्रग कंट्रोल ऑफिसर फरीदाबाद द्वारा गीतांजलि सैलून, फरीदाबाद मॉल से 03 सैंपल, नायका स्टोर, पैसिफिक मॉल, फरीदाबाद से 03 सैंपल, लाइफस्टाइल स्टोर, पैसिफिक मॉल, फरीदाबाद से 03 सैंपल लिए गए।

श्री गहलान ने सत्यजय टाईम्स को बताया कि उक्त सभी सैंपल्स को गुणवत्ता जांच हेतु राजकीय औषधि एवं कॉस्मेटिक्स परीक्षण प्रयोगशाला, चंडीगढ़ में सरकारी विश्लेषक को भेज दिया गया है।

इसी अभियान की निरंतरता में शुक्रवार को रिलायंस रिटेल स्टोर, पलवल से भी 06 कॉस्मेटिक उत्पादों के सैंपल लिए गए हैं, जिन्हें परीक्षण हेतु चंडीगढ़ प्रयोगशाला में भेजा गया है। इसी प्रकार से बल्लभगढ़ क्षेत्र के औषधी नियंत्रण अधिकारी प्रवीण राठी ने छह स्थानों पर से इस प्रकार से सैम्पल लेकर जांच के लिए भेजे हैं। जांच हेतु लिए गए सैंपल्स में भारतीय निर्मित तथा आयातित दोनों प्रकार के कॉस्मेटिक उत्पाद शामिल हैं, जिनमें विभिन्न श्रेणियों के उत्पाद जैसे साबुन, क्रीम, लिपस्टिक, फेस वॉश, शावर जेल, टूथपेस्ट, शैम्पू आदि सम्मिलित हैं। प्रयोगशाला से परीक्षण रिपोर्ट प्राप्त होने के उपरांत नियमानुसार आवश्यक कार्रवाई की जाएगी। श्री गहलान ने बताया कि जनहित एवं उपभोक्ता सुरक्षा को ध्यान में रखते हुए इस प्रकार के विशेष जांच अभियान भविष्य में भी जारी रहेंगे। उन्होंने इन उत्पादों के निर्माताओं से भी अपील की कि वह नियम व कानूनों का ध्यान रख कर उत्पदों का निर्माण सुनिश्चित करें।

फरीदाबाद में संदीप गहलैन, ड्रग कंट्रोल ऑफिसर फरीदाबाद द्वारा गीतांजलि सैलून, फरीदाबाद मॉल से 03 सैंपल, नायका स्टोर, पैसिफिक मॉल, फरीदाबाद से 03 सैंपल लाइफस्टाइल स्टोर, पैसिफिक मॉल, फरीदाबाद से 03 सैंपल लिए गए। जांच हेतु लिए गए सैंपल्स में भारतीय निर्मित तथा आयातित दोनों प्रकार के कॉस्मेटिक उत्पाद शामिल हैं, जिनमें विभिन्न श्रेणियों के उत्पाद जैसे साबुन, क्रीम, लिपस्टिक, फेस वॉश, शावर जेल, टूथपेस्ट, शैम्पू आदि सम्मिलित हैं।

हरियाणा में कॉस्मेटिक उत्पादों की गुणवत्ता की जांच के लिए विशेष अभियान चलाया

फरीदाबाद (जगमार्ग न्यूज)। राज्य औषधि नियंत्रक, हरियाणा ललित गोयल के कार्यालय में कॉस्मेटिक उत्पादों की गुणवत्ता को लेकर लगातार शिकायतें प्राप्त हो रही थीं। उक्त शिकायतों के दृष्टिगत 08 जनवरी 2026 को पूरे हरियाणा राज्य में कॉस्मेटिक उत्पादों के सैंपल लेने हेतु एक विशेष अभियान (स्पेशल ड्राइव) चलाया गया। इस अभियान के अंतर्गत सभी जिलों में रिटेलर्स, होलसेल, मॉल्स एवं जनरल स्टोर्स आदि से कॉस्मेटिक उत्पादों के नमूने लिए गए, ताकि उनकी गुणवत्ता की जांच की जा सके और यह सुनिश्चित किया जा सके कि वे ड्रग्स एंड कॉस्मेटिक अधिनियम एवं नियमों के अनुरूप हैं। जिला फरीदाबाद में, संदीप गहलैन, ड्रग कंट्रोल ऑफिसर, फरीदाबाद द्वारा निम्न स्थानों से सैंपल लिए गए। जिसमें गीतांजलि सैलून, फरीदाबाद मॉल से 03 सैंपल, नायका स्टोर, पैसिफिक मॉल, फरीदाबाद से 03 सैंपल लाइफस्टाइल स्टोर, पैसिफिक मॉल, फरीदाबाद से 03 सैंपल लिए गए। उक्त सभी सैंपल्स को गुणवत्ता जांच हेतु राजकीय औषधि एवं कॉस्मेटिक्स परीक्षण प्रयोगशाला, चंडीगढ़ में सरकारी विश्लेषक को भेज दिया गया है। इसी अभियान की निरंतरता में देर शाम 09 जनवरी को रिलायंस रिटेल स्टोर, पलवल से भी 06 कॉस्मेटिक उत्पादों के सैंपल लिए गए हैं, जिन्हें परीक्षण हेतु चंडीगढ़ प्रयोगशाला में भेजा गया है। जांच हेतु लिए गए सैंपल्स में भारतीय निर्मित तथा आयातित दोनों प्रकार के कॉस्मेटिक उत्पाद शामिल हैं, जिनमें विभिन्न श्रेणियों के उत्पाद जैसे साबुन, क्रीम, लिपस्टिक, फेस वॉश, शावर जेल, टूथपेस्ट, शैम्पू आदि सम्मिलित हैं। जानकारी देते हुए फरीदाबाद ड्रग कंट्रोल ऑफिसर संदीप गहलैन प्रयोगशाला से परीक्षण रिपोर्ट प्राप्त होने के उपरांत नियमानुसार आवश्यक कार्रवाई की जाएगी। जनहित एवं उपभोक्ता सुरक्षा को ध्यान में रखते हुए इस प्रकार के विशेष जांच अभियान भविष्य में भी जारी रहेंगे।

विभाग ने मॉनिटरिंग करते हुए की रेड एमटीपी किट बेचते हुए महिला पकड़ी

भूपेंद्र पंवार | सिरसा

स्वास्थ्य विभाग की टीम ने जाल बिछाकर रेड करते हुए एक महिला को एमटीपी (मेडिकल टर्मीनेशन ऑफ प्रेग्नेंसी) किट बेचते हुए रंगे हाथों पकड़ लिया है। आरोपी महिला के खिलाफ पुलिस में एफआईआर करवा दी है। अब पुलिस आगे की कार्रवाई करेगी। रानियां क्षेत्र में बढ़े गर्भपात के मामलों को देखते हुए विभाग ने रिवर्स ट्रैकिंग की और इसमें कामयाबी भी मिली।

स्वास्थ्य विभाग के अधिकारियों को सूचना मिली कि जिला के गांव भड़ोल्यांवाली में एक आरएमपी व्यक्ति अपने घर में ही एमटीपी किट बेचता है। ऐसे में सिविल सर्जन डॉ. प्रमोद कुमार ने एक टीम का गठन किया। नोडल ऑफिसर डॉ. संजय कुमार के नेतृत्व में बनाई टीम में डॉ. रोकी बांसल, ड्रग कंट्रोलर सुनील कुमार, मनदीप सिंह, दलजीत कुमार, सुंदरपाल को शामिल किया। इसके अलावा डिकोय (जिसे ग्राहक बनाकर भेजा गया) के रूप में एक महिला इंद्रजीत कौर को टीम में लिया। डिकोय को गांव भड़ोल्यांवाली स्थित उक्त व्यक्ति के घर भेजा गया। महिला से एमटीपी किट मांगी तो उन्होंने देना स्वीकार कर लिया व 750 रुपये मांगे। उक्त महिला को पेमेंट करते समय रंगे हाथों पकड़ केस दर्ज कर दिया।

भास्कर इनसाइट

जानिए... कैसे काम आई विभाग की योजना

जिन महिलाओं का गर्भपात होता है, स्वास्थ्य विभाग उनकी सूची तैयार करता है ताकि गर्भपात के कारणों की तलाश और उस पर मंथन किया जा सके। इनमें में भी उन महिलाओं के केस की स्टडी की जाती है जिन महिलाओं के पहला बच्चा लड़की हो और दूसरी बार गर्भवती होने पर गर्भपात हो गया हो। इस प्रक्रिया को रिवर्स ट्रैकिंग कहा जाता है। विभाग नोडल ऑफिसर डॉ. संजय ने 16 ऐसी महिलाओं के केस की रिवर्स ट्रैकिंग की। इसमें खुलासा हुआ कि 8 केस सिर्फ रानियां के हैं। ऐसे में शक हुआ कि इस एरिया में कोई किट बेच रहा है।

नशीली गोलियां मिलने पर मेडिकल सील

भास्कर न्यूज | डबवाली

एंटी नारकोटिक्स सेल डबवाली पुलिस टीम व ड्रग विभाग की संयुक्त टीम ने सुधीर मेडिकोज पर छापेमारी कर 1 लाख 5 हजार 780 नशे में प्रयुक्त होने वाली नशीली गोलियां व कैप्सूल बरामद होने पर मेडिकोज को सील किया गया। एंटी नारकोटिक्स सेल डबवाली प्रभारी एएसआई रणजोध सिंह ने बताया उन्हें सूचना मिली थी कि सुधीर मेडिकोज संचालक कपिल पुत्र सुधीर कुमार वार्ड नंबर 2 मंडी डबवाली नशीली गोलियां व कैप्सूल बेचने का काम करता है। जिसके बाद उन्होंने ड्रग्स विभाग के इंस्पेक्टर सुनील कुमार को मौके पर बुलाकर छापेमारी की। जिसमें नशे में प्रयुक्त होने वाली 200 गोलियां टेपेंडिटोल, 45 कैप्सूल प्रेगाबलीन व 45 गोलियां एलजोप्रोक्स को डीसीओ सिरसा द्वारा कब्जे में लेकर मेडिकल को सील किया गया। संचालक के खिलाफ कार्रवाई की गई। उन्होंने बताया कि जब मेडिकोज संचालक कपिल से गहनता से पूछताछ कर मकान में रेड की गई तो आरोपी के मकान से भारी मात्रा में गोलियों व कैप्सूलों का स्टॉक मिला। जिसमें 10 हजार 950 गोलियां टेपेंडिटोल, 23 हजार 770 कैप्सूल प्रेगाबलीन व 70 हजार 770 गोलियां एलजोप्रोक्स बरामद हुई। जिसके बाद डीसीओ सिरसा द्वारा कब्जे में लेकर आगामी कार्रवाई शुरू कर दी गई है।

प्राइवेट नशा मुक्ति केंद्र में प्रशासनिक टीम का छापा, विशेषज्ञ के बिना चल रहा था इलाज

जांच में सामने आईं गंभीर अनियमितताएं मनमाफिक दे रहे प्रतिबंधित नशीली दवाएं, मेडिकल स्टोर सील

भास्कर न्यूज | डबवाली

शहर के प्राइवेट नशा मुक्ति केंद्रों में बिना विशेषज्ञ डॉक्टर के मरीजों का इलाज हो रहा है।

इतना ही नहीं मन माफिक तरीके से दवाइयां दी जा रही है। जिसमें अधिकतर प्रतिबंधित और नशे में प्रयोग होने वाली है। ऐसा खुलासा प्रशासनिक टीम की गुरुवार को एक नशा मुक्ति केंद्र पर जांच के दौरान हुई है। मामला उजागर होने के बाद प्रशासन ने भी कार्रवाई के लिए आगामी प्रक्रिया शुरू कर दी है। अस्पताल में मेडिकल सील किया गया है।

शहर बठिंडा रोड पर स्थित प्रेरणा हेल्थ केयर मनोरोग एवं नशा मुक्ति केंद्र में दोपहर बाद एसडीएम अर्पित संगल के नेतृत्व में स्वास्थ्य और ड्रग विभाग की टीम पुलिस जाब्ता सहित पहुंची। जिसमें उपमंडल अस्पताल मनोरोग विशेषज्ञ डॉ शुभम बत्रा व एएसएमओ डॉ हरसिमरन की टीम, डीएसपी कपिल अहलावत तथा शहर थाना प्रभारी देवीलाल सहित पुलिस जाब्ता मौजूद रहे। मेडिकल पर जांच और कार्रवाई के लिए ड्रग इंस्पेक्टर केशव वशिष्ठ ने पहुंचकर सील कर दिया है। अस्पताल में अनियमिताओं पर नोटिस दिया है और आगामी कड़ी कार्रवाई के लिए रिपोर्ट तैयार करो अधिकारियों को भेजी गई है।

शहर के प्रेरणा हेल्थ केयर मानसिक रोग एवं नशा मुक्ति केंद्र अस्पताल में प्रशानिक टीम के निरीक्षण दौरान केंद्र में गंभीर अनियमितताएं पाई हैं। टीम ने कहा कि विशेषज्ञ डॉक्टर की अनुपस्थिति में मरीजों को इलाज और दवाइयां दी जा रही थीं। मनोवैज्ञानिक की नियुक्ति नहीं और रिहैबिलिटेशन सुनिश्चित नहीं है।

अस्पताल के मेडिकल और संसाधनों, स्टाफ की कमी पाई। पुरुष व महिला मरीजों के लिए अलग-अलग वार्ड व शौचालय नहीं, साफ-सफाई और मरीजों के उपचार की स्थिति संतोषजनक नहीं मिली। इसके अलावा बॉयो-मेडिकल वेस्ट के निस्तारण की उचित व्यवस्था नहीं थी। अस्पताल में बने मेडिकल से मरीजों को मनमाफी की दवाइयां दी जा रही थी जिसमें कम डोज और मात्रा की जरूरत वाले मरीजों को भी भरपूर दवाई दी जा रही है। इसके नशे में दुरुपयोग की भी सूचना है।

गड़बड़ी की थी शिकायत

सूत्रों के मुताबिक शहर के नशा मुक्ति केंद्रों में मरीज को इलाज के नाम पर नशीली दवाइयां दी जा रही है और परिजन बिल भुगतान करते हुए परेशान हो चुके हैं। इसको लेकर कई बार सूचना और शिकायत मिल रही है। जिसके चलते एसडीएम के नेतृत्व में प्रशासनिक और ड्रग विभाग तथा पुलिस की टीम गठित कर कार्रवाई की गई है।

इस बारे में एसडीएम अर्पित संगल ने बताया कि नशा मुक्ति केंद्र में गड़बड़ी की सूचना मिलने के उपरांत टीम ने एक्शन लिया है। प्रेरणा मनोरोग एवं नशा मुक्ति केंद्र की छापेमारी में मेडिकल सील किया है और अस्पताल में कई कमियां सामने आई हैं।

FDA Haryana in news

पहली बार फरीदाबाद, पलवल व बल्लभगढ़ में चली ड्राइव

ब्यूटी प्रॉडक्ट्स जांच के घेरे में, अभियान चला 27 सैंपल लिए

■ गौरी शर्मा, फरीदाबाद

मिलावटी ब्यूटी प्रॉडक्ट्स कहीं आपके चेहरे की सुंदरता न छीन ले, इसी के मद्देनजर हरियाणा सरकार ने एक खास अभियान चलाया। हरियाणा के राज्य औषधि नियंत्रक, ललित गोयल के निर्देश पर पूरे प्रदेश में कई जगहों पर कॉस्मेटिक्स उत्पादों की गुणवत्ता की जांच की गई। इसके तहत फरीदाबाद में 15, बल्लभगढ़ और पलवल में 6-6 सैंपल लिए गए। मॉल से लेकर सैलून व ब्रैंडेड कॉस्मेटिक्स शॉप तक शामिल हैं। सभी सैंपल्स को सील कर राजकीय औषधि एवं कॉस्मेटिक्स परीक्षण प्रयोगशाला चंडीगढ़ में भेजा गया है।

अधिकारियों के अनुसार, रिपोर्ट आने के बाद अगर कोई उत्पाद महिलाओं की त्वचा या स्वास्थ्य के लिए हानिकारक पाया जाता है तो संबंधित कंपनी और विक्रेता के खिलाफ सख्त कानूनी कार्रवाई की जाएगी। जरूरत पड़ने पर ऐसे उत्पादों को बाजार से हटाया जाएगा।

लगातार आ रही थी शिकायतें: राज्य औषधि नियंत्रक कार्यालय के पास कुछ समय से क्रीम, लिपस्टिक, फेसवॉश, शैम्पू और अन्य खराब ब्यूटी प्रॉडक्ट्स को लेकर शिकायतें आ रही थीं। इनमें बताया गया कि इनके यूज से त्वचा एलर्जी, जलन, बालों के झड़ने जैसी दिक्कतें देखी गईं। इसके बाद यह अभियान चलाया गया। इसके तहत सभी जिलों में ड्रग कंट्रोल विभाग की टीमें ने ब्यूटी सैलून, कॉस्मेटिक स्टोर्स, शॉपिंग मॉल्स और जनरल स्टोर्स का निरीक्षण किया। सैंपल लेकर जांच को भेजे गए।

> महिलाओं की सेहत हमारी प्राथमिकता है। ब्यूटी प्रॉडक्ट्स के नाम पर मानकों से समझौता बर्दाश्त नहीं किया जाएगा। यह अभियान भविष्य में भी जारी रहेगा।
> -ललित गोयल, राज्य औषधि नियंत्रक, हरियाणा

कई जगहों पर कॉस्मेटिक्स उत्पादों की हुई जांच

फरीदाबाद में लिए 15 सैंपल

फरीदाबाद में ड्रग कंट्रोल ऑफिसर (डीसीओ) संदीप गहलैन के नेतृत्व में महिलाओं से जुड़े सौंदर्य उत्पादों पर विशेष नजर रखी गई। फरीदाबाद मॉल स्थित सैलून, पैसिफिक मॉल स्थित दो स्टोर से कुल 9 कॉस्मेटिक उत्पादों के सैंपल लिए गए। सभी सैंपल्स को सील कर राजकीय औषधि एवं कॉस्मेटिक्स परीक्षण प्रयोगशाला, चंडीगढ़ भेजे दिए गए। इसी कड़ी में शुक्रवार को पलवल जिले के बड़े रिटेल स्टोर से भी 6 कॉस्मेटिक्स उत्पादों के सैंपल लिए गए। इनमें साबुन, फेयरनेस, मॉइस्चराइजिंग क्रीम, लिपस्टिक, फेस वॉश, शॉवर जेल, टूथपेस्ट और शैम्पू जैसे उत्पाद शामिल है। वहीं, बल्लभगढ़ में भी 6 सैंपल कलेक्ट किए।

आप भी कर सकते हैं कंप्लेंट

जिले में पहली बार आदेश जारी हुए जिसके तहत यह चेकिंग की गई थी। महीने में करीब 5 से 7 कंप्लेन आते है। ऐसे में अगर जिले में कोई इससे संबंधित शिकायत करना चाहता है मेल आईडी fdaharyana@gmail.com पर भेज सकता है।

विशेषज्ञ की राय 'पैच टेस्ट' के बिना न करें इस्तेमाल

बीके अस्पताल के त्वचा रोग विशेषज्ञ डॉ. दारा सिंह ने बताया...

- उत्पाद खरीदने से पहले मैन्युफैक्चरिंग, एक्सपायरी डेट व इस्तेमाल की गई सामग्री चेक करें।
- नए ब्यूटी प्रॉडक्ट को सीधे चेहरे पर लगाने के बजाय हाथ पर लगाएं
- अत्यधिक केमिकल युक्त उत्पाद पिगमेंटेशन और परमानेंट स्किन डैमेज का कारण बन सकते है।

AI ने बताया, इनमें किस चीज की होती है मिलावट और उसके नुकसान

1. **मरकरी (पारा) :** फेयरनेस/स्किन व्हाइटनिंग क्रीम में करते है यूज।
   नुकसान: इसकी ज्यादा मात्रा त्वचा में जलन, लंबे समय में नर्वस सिस्टम पर असर पड़ सकता है
2. **सीसा (Lead) :** लिपस्टिक, काजल, सिंदूर में डालते है।
   नुकसान: होठ काले पड़ना, हार्मोन असंतुलन, गर्भवती के लिए खतरनाक
3. **स्टेरॉयड्स :** फेयरनेस और एंटी-एजिंग क्रीम में फायदे के लिए यूज करते है
   नुकसान: दाने, स्थायी दाग-धब्बे
4. **PPD (पैराफिनिलीन डायमीन)**
   कहां: हेयर डाई
   नुकसान: एलर्जी, आख/चेहरे की सूजन, सांस लेने में दिक्कत
6. **फॉर्मेल्डिहाइड :** नेल पॉलिश, हेयर स्ट्रेटनिंग प्रॉडक्ट
   नुकसान: आंखो में जलन, कैंसर का कारक हो सकता है

कैसे पहचानें मिलावट

- कम कीमत में ब्रैंडेड जैसा प्रॉडक्ट
- तेज/असामान्य खुशबू या रंग
- पैकिंग पर मैन्युफैक्चरर, बैच नंबर, एक्सपायरी न हो
- लगाने पर जलन, खुजली या लालपन तुरंत होना

सुरक्षित रहने के उपाय

- BIS/ISI या CDSCO अप्रूव्ड प्रॉडक्ट चुनें
- ऑनलाइन में ऑफराइज्ड सेलर से ही खरीदें, फेयरनेस के नाम पर तुरंत असर देने वाले दावों से बचें

कॉस्मेटिक उत्पादों की गुणवत्ता की जांच के लिए विशेष अभियान

अमर भारती संवाददाता, फरीदाबाद। राज्य औषधि नियंत्रक, हरियाणा श्री ललित गोयल के कार्यालय में कॉस्मेटिक उत्पादों की गुणवत्ता को लेकर लगातार शिकायतें प्राप्त हो रही थीं। उक्त शिकायतों के दृष्टिगत दिनांक 08 जनवरी 2026 को पूरे हरियाणा राज्य में कॉस्मेटिक उत्पादों के सैंपल लेने हेतु एक विशेष अभियान (स्पेशल ड्राइव) चलाया गया। इस अभियान के अंतर्गत सभी जिलों में रिटेलर्स, होलसेलर्स, मॉल्स एवं जनरल स्टोर्स आदि से कॉस्मेटिक उत्पादों के नमूने लिए गए, ताकि उनकी गुणवत्ता की जांच की जा सके और यह सुनिश्चित किया जा सके कि वे ड्रग्स एंड कॉस्मेटिक्स अधिनियम एवं नियमों के अनुरूप हैं। जिला फरीदाबाद में, संदीप गहलैन, ड्रग कंट्रोल ऑफिसर, फरीदाबाद द्वारा निम्न स्थानों से सैंपल लिए गए। जिसमें गीतांजलि सैलून, फरीदाबाद मॉल से 03 सैंपल, नायका स्टोर, पैसिफिक मॉल, फरीदाबाद से 03 सैंपल लाइफस्टाइल स्टोर, पैसिफिक मॉल, फरीदाबाद से 03 सैंपल लिए गए। उक्त सभी सैंपल्स को गुणवत्ता जांच हेतु राजकीय औषधि एवं कॉस्मेटिक्स परीक्षण प्रयोगशाला, चंडीगढ़ में सरकारी विश्लेषक को भेज दिया गया है। इसी अभियान की निरंतरता में देर शाम 09 जनवरी को रिलायंस रिटेल स्टोर, पलवल से भी 06 कॉस्मेटिक उत्पादों के सैंपल

लिए गए हैं, जिन्हें परीक्षण हेतु चंडीगढ़ प्रयोगशाला में भेजा गया है। जांच हेतु लिए गए सैंपल्स में भारतीय निर्मित तथा आयातित दोनों प्रकार के कॉस्मेटिक उत्पाद शामिल हैं, जिनमें विभिन्न श्रेणियों के उत्पाद जैसे साबुन, क्रीम, लिपस्टिक, फेस वॉश, शावर जेल, टूथपेस्ट, शैम्पू आदि सम्मिलित हैं। जानकारी देते हुए फरीदाबाद ड्रग कंट्रोल ऑफिसर संदीप गहलैन प्रयोगशाला से परीक्षण रिपोर्ट प्राप्त होने के उपरांत नियमानुसार आवश्यक कार्रवाई की जाएगी। जनहित एवं उपभोक्ता सुरक्षा को ध्यान में रखते हुए इस प्रकार के विशेष जांच अभियान भविष्य में भी जारी रहेंगे।

Affix warning labels on solvents: Hry FDA to pharma companies

HT Correspondent
letterschd@hindustantimes.com

CHANDIGARH: *Following nationwide detection of consignments of contaminated cough syrups, the Haryana Food and Drugs Administration (FDA) on Wednesday directed pharmaceutical manufacturers across the state to ensure that warning labels are found affixed on high-risk industrial grade solvents.*

The FDA had earlier banned sale, distribution and use of certain brands of cough syrups after diethylene glycol, a toxic chemical known to cause serious health complications, including acute poisoning, kidney failure, neurological disorders, and even death, particularly among children, was detected in the formulations.

State Drugs Controller Lalit Goel, in a December 31 communication to pharmaceutical manufacturers, said that the Enforcement Division of Central Drugs Standard Control Organisation, Directorate General Health Services in the central government had on December 22 issued directives to curb the sale of industrial-grade high-risk solvents and certain excipients without adequate safeguards. The directions also aimed at stopping their potential misuse and curb public health risks besides strengthening regulatory oversight and ensuring safety in the pharmaceutical supply chain.

"All traders, manufacturers, importers and distributors dealing in industrial-grade high-risk solvents must ensure that each container of such solvents bears clear, legible label stating -not for pharmaceutical use. The warning must also be printed prominently on the sale invoice, delivery challan, and any other transaction document issued during the sale of these solvents," the state drugs controller said.

The communication further said that sale of excipients must be done only in original tamper-proof containers and all high-risk solvents must be sold only in sealed, original tamper-proof containers with complete labelling and batch-traceability information.

Immediate ban ordered on batch of cough syrup

CHANDIGARH, JANUARY 9

Health Minister Arti Singh Rao on Friday instructed Health Department officials to be vigilant about substandard medicines and to take immediate action if they receive any complaints about the sale of medicines that do not meet quality standards.

She today ordered immediate ban on a batch of medicine 'Almont-Kid (Levocetirizine Dihydrochloride and Montelukast Sodium Syrup)' after it was found to contain ethylene glycol in quantities exceeding the prescribed limit.

She directed the issuance of a public health alert in the state regarding the presence of this harmful chemical in the cough syrup. The State Drugs Controller of the Haryana Food and Drug Administration, Lalit Kumar Goyal, informed that the batch number of the said medicine is AL-24002 with a manufacturing date of January 2025 and an expiry date of December 2026. This medicine is manufactured by M/s Tridus Remedies, Hajipur, Vaishali (Bihar).

Arti Singh Rao stated that based on official information received from the Central Drugs Standard Control Organisation (CDSCO), Eastern Region, Kolkata, the Haryana Food and Drug Administration (FDA) found a sample of the medicine to be substandard. — TNS

FDA Haryana in news

Govt monitoring medicine prices: Arti Rao

TRIBUNE NEWS SERVICE

CHANDIGARH, JANUARY 2

Health Minister Arti Singh Rao said the state government was committed to ensure availability of affordable and essential medicines for the general public. "With this objective, strict monitoring of medicine prices is done in Haryana to effectively curb overcharging at any level," she said.

The Health Minister said, "Under guidelines of the

'Use Pharma Sahi Daam app'

National Pharmaceutical Pricing Authority (NPPA), the Price Monitoring and Resource Unit (PMRU) is actively functioning in Haryana under the Food and Drugs Administration (FDA) Department. This unit is ensuring that medicines are available for citizens only at rates fixed by the government."

She said, "The objective is to ensure that life-saving medicines are available for every citizen at reasonable and regulated prices. All these measures are being taken keeping in view Haryana residents health and welfare."

Manoj Kumar, Commissioner, Food and Drugs Administration, said during 2025, 33 cases of overcharging of medicines were reported in Haryana, which were sent to the NPPA, New Delhi, for action. "This reflects the government's strict and transparent policy, under which no compromise will be made with the public health," he said.

He said in December, the Haryana PMRU detected violations of the Drug Price Control Order in three medicines, wherein the MRP was found to be higher. He appealed to the public to use the Pharma Sahi Daam appl to check the prices.

Affix warning labels on solvents: Hry FDA to pharma companies

HT Correspondent

letterschd@hindustantimes.com

CHANDIGARH: Following nationwide detection of consignments of contaminated cough syrups, the Haryana Food and Drugs Administration (FDA) on Wednesday directed pharmaceutical manufacturers across the state to ensure that warning labels are found affixed on high-risk industrial grade solvents.

The FDA had earlier banned sale, distribution and use of certain brands of cough syrups after diethylene glycol, a toxic chemical known to cause serious health complications, including acute poisoning, kidney failure, neurological disorders, and even death, particularly among children, was detected in the formulations.

State Drugs Controller Lalit Goel, in a December 31 communication to pharmaceutical manufacturers, said that the Enforcement Division of Central Drugs Standard Control Organisation, Directorate General Health Services in the central government had on December 22 issued directives to curb the sale of industrial-grade high-risk solvents and certain excipients without adequate safeguards. The directions also aimed at stopping their potential misuse and curb public health risks besides strengthening regulatory oversight and ensuring safety in the pharmaceutical supply chain.

"All traders, manufacturers, importers and distributors dealing in industrial-grade high-risk solvents must ensure that each container of such solvents bears clear, legible label stating -not for pharmaceutical use. The warning must also be printed prominently on the sale invoice, delivery challan, and any other transaction document issued during the sale of these solvents," the state drugs controller said.

The communication further said that sale of excipients must be done only in original tamper-proof containers and all high-risk solvents must be sold only in sealed, original tamper-proof containers with complete labelling and batch-traceability information.

फतेहाबाद में मेडिकल स्टोर्स पर पुलिस प्रशासन, नारकोटिक्स ब्यूरो और ड्रग विभाग की ज्वाइंट रेड

एक साथ 34 मेडिकल स्टोर खंगाले, 28 में नियमों की अनदेखी उजागर

रिकॉर्ड अधूरे, फार्मासिस्ट गायबछह्नजनता की सेहत से खुला खिलवाड़

अक्षय कुमार शर्मा

पंचकूला/फतेहाबाद : फतेहाबाद जिले में दवा कारोबार की स्थिति को लेकर और पुलिस अधीक्षक फतेहाबाद की गुप्त सूचना के आधार पर हरियाणा खाद्य एवं औषधि प्रशासन ने सख्त रुख अपनाते हुए व्यापक छापेमारी अभियान चलाया। आयुक्त मनोज कुमार (आईएएस) तथा राज्य औषधि नियंत्रक ललित गोयल के निर्देश पर पुलिस और नारकोटिक्स नियंत्रण से जुड़े विभागों के सहयोग से यह संयुक्त कार्रवाई की गई।अभियान के तहत राज्य के विभिन्न जिलों से आए आठ औषधि नियंत्रण अधिकारियों की टीमें सिरसा जोन के वरिष्ठ औषधि नियंत्रण अधिकारी के पर्यवेक्षण में गठित की गईं। इन टीमों ने फतेहाबाद शहर के साथ-साथ सदर, टोहाना, रतिया, भट्टू कलां और जाखल जैसे क्षेत्रों में एक साथ दबिश देकर मेडिकल स्टोरों की गहन जांच की।जांच के दौरान कुल 34 मेडिकल स्टोरों को खंगाला गया। किसी भी दुकान से नशीली दवाओं की बरामदगी नहीं हुई, लेकिन निरीक्षण में सामने आई खामियों ने दवा व्यवस्था की गंभीर लापरवाही को उजागर कर दिया। कई दुकानों पर दवा बिक्री के रिकॉर्ड अधूरे पाए गए, जबकि अनेक स्थानों पर पंजीकृत फार्मासिस्ट अनुपस्थित मिले। दवाओं के भंडारण और बिक्री में कानूनी नियमों की अनदेखी भी दर्ज की गई। प्रशासनिक आकलन के अनुसार 34 में से 28 मेडिकल स्टोरों पर नियम उल्लंघन पाया गया।इस कार्रवाई में अमनदीप (गुरुग्राम-प्रथम), अजय कुमार (हिसार), सुरेश वर्मा (गुरुग्राम-द्वितीय), मुकेश (गुरुग्राम-तृतीय), दिनेश राणा (फतेहाबाद-प्रथम), सुरेंद्र (भिवानी), प्रशांत (नारनौल) और केशव (सिरसा-तृतीय) ने मोर्चा संभाला।

अधिकारियों ने दो टूक कहा कि बिना फार्मासिस्ट और बिना वैध रिकॉर्ड के दवाओं की बिक्री जनता की सेहत से सीधा खिलवाड़ है। दवा जीवन रक्षक वस्तु है, इसमें लापरवाही को बर्दाश्त नहीं किया जाएगा।

औषधि नियंत्रक ललित गोयल ने स्पष्ट किया है कि सभी निरीक्षण रिपोर्ट प्राप्त होने के बाद औषधि एवं प्रसाधन सामग्री अधिनियम के तहत सख्त कानूनी कार्रवाई की जाएगी। फिलहाल किसी दुकान को सील नहीं किया गया है, लेकिन संकेत साफ हैं कि आगामी दिनों में निगरानी और कार्रवाई दोनों और तेज होंगी।

कार्रवाई • फतेहाबाद में भट्टू रोड, पंचायत भवन और रतिया चुंगी पर बने मेडिकल स्टोर खंगाले

7 साल बाद 10 सदस्यीय ड्रग इंस्पेक्टरों की टीम ने जिले में एक साथ कई मेडिकल स्टोर्स पर मारे छापे

भास्कर न्यूज | फतेहाबाद/टोहाना/रतिया

जिले में बढ़ते मेडिकल नशे और इससे हो रही युवाओं की मौतों ने पुलिस व स्वास्थ्य विभाग की चिंता बढ़ा दी है। इसी कड़ी में जहां एक ओर पुलिस नशा तस्करों के ठिकानों पर दबिश दे रही है, वहीं करीब 10 साल बाद स्वास्थ्य विभाग की 10 सदस्यीय ड्रग इंस्पेक्टरों की विशेष टीम ने जिले भर में कई मेडिकल स्टोरों पर एक साथ छापेमारी कर रिकॉर्ड की गहन जांच की। मेडिकल नशे के बढ़ते मामलों के बाद ड्रग विभाग पर सवाल उठ रहे थे।

रतिया क्षेत्र में मेडिकल नशे के कारण हाल ही में दो युवकों की संदिग्ध मौत के बाद पुलिस प्रशासन अलर्ट हो गया है। गुरुवार रात करीब 8 बजे एएसपी दिव्यांशी सिंगला ने टीम के साथ रतिया के गुरुनानकपुरा मोहल्ले में नशा तस्करों के ठिकानों पर सर्च अभियान चलाया। इस दौरान एक घर से रेगिंग सेक्शन में इस्तेमाल होने वाली सिरिंज पर्ची और 5 व 10 रुपये के नोट बरामद किए गए। पुलिस को देखकर कई युवक मौके से फरार हो गए, जबकि कुछ से पूछताछ कर उनके घरों की तलाशी ली गई।

रतिया। मेडिकलो की जांच करते ड्रग्स विभाग की टीम।

मेडिकल संचालक बोले- हम हर संभव मदद करेंगे

मेडिकल एसोसिएशन ने भी नशे के खिलाफ प्रशासन का साथ देने की बात दोहराई है। फतेहाबाद मेडिकल एसोसिएशन के प्रधान रवि भाना ने कहा कि यदि कोई मेडिकल संचालक नशे में इस्तेमाल होने वाली दवाइयां बेचता पाया गया तो एसोसिएशन उसका कोई सहयोग नहीं करेगी। एसपी सिद्धांत जैन ने कहा है कि जिले में मेडिकल नशे की रोकथाम को लेकर पुलिस पूरी तरह गंभीर है। नशे के कारण युवाओं की जान जाना बेहद चिंताजनक है। इसी वजह से पुलिस और स्वास्थ्य विभाग मिलकर संयुक्त रूप से कार्रवाई कर रहे हैं। नशा तस्करों, अवैध सप्लाई चेन और मेडिकल नशे से जुड़े लोगों पर सख्त नजर रखी जा रही है। जहां भी शिकायत या पुख्ता सूचना मिलेगी, वहां तुरंत दबिश दी जाएगी।

यहां चलाए गए चेकिंग अभियान

दूसरी ओर, स्वास्थ्य विभाग की 10 सदस्यीय टीम ने फतेहाबाद जिले में अलग-अलग स्थानों पर ड्रग इंस्पेक्टर तैनात कर एक साथ चेकिंग अभियान चलाया। फतेहाबाद शहर में रतिया चुंगी क्षेत्र के दो मेडिकल, पंचायत घर के सामने स्थित एक मेडिकल, भट्टू रोड पर एक और अन्य दो मेडिकल स्टोरों की जांच की गई। टीम ने प्रतिबंधित दवाइयों की बिक्री, स्टॉक रजिस्टर, बिल और लाइसेंस से जुड़े दस्तावेज खंगाले। जांच में कोई संदिग्ध दवा बरामद नहीं हुई, लेकिन मेडिकल संचालकों को सख्त हिदायत दी गई।

2015 में भी उठा था मामला, मंत्री रिज और एसपी संगीता के बीच हुई थी तीखी तकरार

वर्ष 2015 में जिला कष्ट निवारण समिति की बैठक के दौरान तत्कालीन मंत्री अनिल विज और उस समय की एसपी संगीता कालिया के बीच नशे के मामलों को लेकर तीखी तकरार हुई थी। बैठक में पुलिस पर नशा न रोक पाने के गंभीर आरोप लगे थे। इसके बाद दैनिक भास्कर ने ग्राउंड रिपोर्ट कर खुलासा किया था कि रतिया क्षेत्र, खासकर ग्रामीण इलाकों में मेडिकल नशे का बड़े पैमाने पर प्रयोग हो रहा है। रिपोर्ट सामने आने के बाद ड्रग विभाग की 10 से अधिक टीमों ने एक साथ चेकिंग अभियान चलाया था, जिसमें कई खामियां उजागर हुई थीं और अनेक मेडिकल स्टोर सील किए गए थे।

DFCO J&K

Drug & Food Control Organization (UT J&K) Seizes Habit-Forming Drugs Worth ₹5.57 Lakh in District Poonch, Courier Bust.

Poonch

30.01.2026

In District POONCH, Jan 30: As part of its ongoing drive against illegal trafficking of habit-forming pharmaceutical drugs, the Drugs & Food Control Organization (DFCO) intercepted and seized a large consignment of medicines being transported illegally through a private courier service in the Mendhar area of Poonch district.

The seized consignment comprised 15,000 unit doses worth ₹5,57,500, including 10,000 capsules of Pregabalin-300 and 5,000 tablets of Tapentadol-100.

The drugs were found concealed in a suspicious parcel without valid documents and were allegedly meant for unauthorized sale. During inspection, the DTDC parcel was opened in the presence of authorized personnel, following which the illegal stock was detected.

Vikas, Drug Control Officer seized the consignment on the spot under Form-16, in accordance with the provisions of the Drugs & Cosmetics Act, 1940. Preliminary investigation revealed that the drugs were being routed into Jammu & Kashmir from a neighboring State.

Authorities are verifying the source and destination of the parcel and the details of the consignee to initiate legal action.

The operation was carried out by Drugs Control Officer Poonch, Vikas Sharma, under the supervision of Assistant Drugs Controller Rajouri/Poonch, Archana Mujoo, with active cooperation from the courier service provider.

State Drugs Controller, J&K, Rajesh Kumar, appreciated the cooperation of the courier agency and urged all such service providers to assist the Government in curbing illegal drug movement.

Commissioner, FDA J&K, Smita Sethi, also lauded the DFCO team and reiterated the Government's commitment to eliminating illegal drug trafficking through sustained enforcement and coordinated action.

Source: Shabir Ahmad Pandit (J&K)

Telangana

Hyderabad: 'Goat Blood Scandal' Uncovered – 1,000 Litres Of Animal Blood Packed In Human Blood Bags Seized From Import-Export Firm

DCA Telangana

Hyderabad, January 11, 2026:

In a chilling revelation that has stunned health authorities and sparked widespread outrage, a joint raid by the Telangana Drugs Control Administration (DCA), Central Drug Control officials, and Hyderabad City Police uncovered nearly 1,000 litres of illegally collected animal blood — primarily from goats and sheep — stored in blood bags designed exclusively for human use.

The dramatic bust, conducted on January 8, 2026, targeted CNK Import Export Company in the Kachiguda area of Hyderabad, following specific intelligence inputs.

The operation began with an initial seizure at a butcher shop in Keesara, where around 130-150 blood packets (each containing 300-350 ml) were recovered from live animals, leading investigators to trace the supply chain to the Kachiguda firm.

During the raid, authorities discovered:

110 filled blood bags and approximately 60 empty blood bags, all intended for human blood storage and transfusion.

Sophisticated equipment including an autoclave machine (a regulated medical device) and a laminar air flow unit — used for sterile blood transfer to prevent contamination — indicating advanced processing of the blood.

The blood was allegedly extracted from live sheep and goats in isolated locations around Keesara, with the firm's owner, Nikesh, paying butchers ₹2,000 to ₹3,000 per bag and supplying the human-grade blood bags himself.

Drug inspectors expressed profound shock at the unprecedented modus operandi. One veteran inspector with 15 years of service stated: “In my entire career, I have never seen such a thing.

I have never witnessed goat blood or any other animal blood being collected in bags meant for human blood.

No licence is issued to collect blood in human blood bags.”

Senior officials highlighted the grave dangers: “If even by mistake animal blood is supplied to any hospital, it can lead to fatal consequences.

Animal blood given to humans is invariably fatal.” Blood is strictly regulated as a drug under

(Continued on page 47)

Telangana

(Continued from page 46)

the Drugs and Cosmetics Act, requiring precise matching of human blood groups — a mismatch can be deadly, and inter-species transfusion is catastrophic.

The premises have been sealed, and samples of the seized blood have been sent for laboratory analysis.

A case has been registered under Section 18(c) of the Drugs and Cosmetics Act at Keesara Police Station.

Investigations are also probing potential violations of animal cruelty laws, given reports of extraction from live animals without veterinary oversight or permissions.

The prime suspect, Nikesh, the owner of CNK Import Export Company (registered only as a general import-export entity with no licenses for blood handling or regulated medical devices), is absconding.

He reportedly fled after removing key documents but left the blood bags behind. Police have launched a manhunt.

Preliminary findings suggest the blood was being dispatched to a Haryana-based firm, Polymedicure Company, though the exact end-use remains unclear and is the focal point of the ongoing probe.

Authorities suspect possible misuse in:

Unauthorized clinical trials or experimental research.

Preparation of culture media for bacterial growth in labs.

Extraction of serum (yielding about 200 ml from 500 ml of blood) for applications in skin treatments, hair products, cosmetics, or even vaccine production.

This "Goat Blood Scandal" has exposed alarming gaps in oversight of biomedical supply chains and raised serious questions about how such a large-scale, systematic operation went undetected.

It also highlights the potential risks of unregulated animal-derived materials entering medical or research ecosystems.

The DCA and police have vowed to expand the investigation nationwide, tracing any wider networks and ensuring strict legal action.

Health experts have urged heightened vigilance in blood supply chains, while animal welfare groups have condemned the alleged cruelty in live extractions.

As the probe deepens, this bizarre and disturbing incident serves as a stark reminder of the need for robust regulation in India's pharmaceutical and biomedical sectors to prevent life-threatening misuse.

Further updates are awaited as the absconding owner is apprehended and lab results confirm the blood's composition and potential applications.

Source: G Koteshwar Rao

Telangana

1

GOVERNMENT OF TELANGANA
DRUGS CONTROL ADMINISTRATION

Press Note

Press Note No. 01/DCA/2026 **Date: 07-01-2026**

Drugs Control Administration, Telangana raided a quack's clinic in Damera Village, Elkathurthi Mandal, Hanumakonda District, and seized drugs illegally stocked for sale.

*****

The details are as follows:

On credible information, Drugs Control Administration officials, on 6th January, 2026 raided the premises of a quack/unqualified practitioner Swargam Sathish Babu, situated at First Aid Clinic, Damera Village, Elkathurthi Mandal, Hanumakonda District, who was conducting clinical practice without proper qualifications at his clinic.

During the raid, DCA officials detected **30 varieties** of medicines, including antibiotics, steroids, analgesics, anti-ulcer drugs, antihypertensive drugs, etc. stocked at the premises without a drug licence. Worth of the stock seized is Rs. 21,650/-.

DCA officials detected several **'antibiotics'** at the clinic during the raid. The indiscriminate sale of antibiotics by unqualified persons may have disastrous consequences on the health of public, including the emergence of **'Antimicrobial Resistance'**.

Telangana

2

Officials found **'steroids'** at the clinic of the quack. Misusing steroids can have serious health consequences, including immune system suppression, hormonal imbalances, muscle and bone weakness, cardiovascular problems, and psychological effects. The indiscriminate use of steroids poses significant risks to public health.

Sri. J. Kiran Kumar, Drugs Inspector, Hanumakonda carried out the raid under the supervision of Dr. G. Rajyalakshmi, Assistant Director, Warangal.

DCA officers lifted the samples for analysis. Further investigation will be carried out, and action will be taken as per the law against all the offenders.

ADVISORY

It is hereby informed that Wholesalers/Dealers supplying medicines to **quacks, other unqualified persons, and unlicensed shops**, who are found stocking and selling drugs without a valid drug license, shall be liable for penal action under the provisions of the Drugs and Cosmetics Act, 1940. Stringent action shall be initiated against such Wholesalers/Dealers involved unauthorized and illegal supply chains.

All Wholesalers/Dealers are mandatorily directed to ensure that medicines are supplied only to entities holding a valid drug license issued by the competent Licensing Authority. It is the responsibility of every Wholesaler/Dealer to verify and maintain records of the validity of drug licenses of recipient establishments before effecting supplies. Non-compliance in this regard will attract strict action as per law.

The Drugs Control Administration, Telangana, issues drug licenses for the stocking and selling of medicines in accordance with the provisions of the

Telangana

3

Drugs and Cosmetics Act. **Stocking drugs for sale without a drug license is punishable under the Drugs and Cosmetics Act, with imprisonment for up to five years.**

****

The public may report any complaints regarding illegal activities related to medicines, as well as any other suspected manufacturing activities concerning drugs, including narcotic drugs and psychotropic substances, in residential, commercial, or industrial areas through the Drugs Control Administration, Telangana Toll-Free Number 1800-599-6969, operational from 10:30 am to 5:00 pm on all working days.

Date: 07-01-2026

SHAHNAWAZ QASIM, IPS
DIRECTOR GENERAL

Photograph - Raid at quack's clinic in Damera Village, Elkathurthi Mandal, Hanumakonda District

*****

Telangana

1

GOVERNMENT OF TELANGANA
DRUGS CONTROL ADMINISTRATION

Press Note

Press Note No. 03/DCA/2026 **Date: 13-01-2026**

Drugs Control Administration, Telangana, seized Spurious Drug (Counterfeit Version) 'Levipil 500' Tablets (Levetiracetam Tablets 500 mg), falsely claimed to be manufactured by Sun Pharma Laboratories Ltd.

Levipil 500 Tablet is an anti-epileptic medicine used to treat seizures (fits) in epilepsy.

Based on intelligence gathered by Drugs Control Administration officials, raids were conducted at several dealers in the State, leading to the detection of a **Spurious Drug – a Counterfeit Version** of **'Levipil 500' Tablets** (Levetiracetam Tablets 500 mg) – circulating in the market.

During the raids, a special team of officers of the Drugs Control Administration detected counterfeit stocks of **Levipil 500 Tablets** at the premises of **Durga Medical and General Stores,** located in Sudharsan Reddy Nagar, Chintal, Quthbullapur Village, Quthbullapur Mandal, Medchal-Malkajgiri District.

On 12th January, 2026, counterfeit version of 'Levipil 500' Tablets (Levetiracetam Tablets 500 mg), bearing Batch No.: GTF0885A, Mfg. Date: April-2024, Exp. Date: March-2026, and falsely claimed to be manufactured by Sun Pharma Laboratories Ltd., Vill. Kokjhar, Dist. Kamrup, Assam, was seized.

Further investigation will be conducted, and appropriate action will be taken against all offenders involved.

Spurious drugs pose a significant threat to public health, endangering patients' well-being. These drugs not only fail to treat the intended disease but also can lead to severe health complications over time.

DCA is actively working to ensure the removal of spurious drugs from the market.

****

The public may report any complaints regarding illegal activities related to medicines, as well as any other suspected manufacturing activities concerning drugs, including narcotic drugs and psychotropic substances, in residential, commercial, or industrial areas through the Drugs Control Administration, Telangana Toll-Free Number 1800-599-6969, operational from 10:30 am to 5:00 pm on all working days.

Date: 13-01-2026

SHAHNAWAZ QASIM, IPS
DIRECTOR GENERAL

Counterfeit Version of 'Levipil 500' Tablets (Levetiracetam Tablets 500 mg), Batch No.: GTF0885A Seized by DCA



Best Wishes On Promotion

The DCOIWA family extends its best wishes for the future endeavors of the officers who have recently assumed their positions as the Head of Department / State Drugs Controller / Controlling Authority / State Licensing Authority following their well-deserved promotions.

Sh. Rajeev Bhargav has been appointed as Drugs Controller of NCT Delhi

Sh. Rajesh Kumar has been appointed as in-charge Drugs Controller of Jammu & Kashmir

Sh. Vitthal Dobaria, Deputy Commissioner, FDCA Gujarat

Best Wishes On Promotion

The DCOIWA family extends its best wishes for the future endeavors of the officers who have recently assumed their positions as Deputy commissioner.

Promotions: FDCA Gujarat

Sh. PM Pusnani, Deputy commissioner

Sh. N R Saiyed, Deputy commissioner

Sh. V D Dobaria, Deputy commissioner

Sh. JP Patel, Deputy commissioner

Best Wishes on retirement

The DCOIWA family extends its best wishes for the future endeavours of the following officer who have recently retired. May God bless them with all happiness and healthy life.



Shri. Azaz Ahamad, Assistant Commissioner Drug, UP

RETIREMENTs from Bihar State:

- **Sh. Amod Kumar, ADC**
- **Sh. Rajesh Gupta, ADC**
- **Sh. K K Sherma, DI**
- **Sh. Jamilur Rahman, DI**
- **Sh. Jay Shankar Prasad, DI**

Congratulations

Laughter dose

Source: PK Jaggi, Co-Editor

New Members of DCOIWA





How to become a member

Register Online

Download Form



Republic Day 2026 Awards: J&K

Republic Day 2026 Awards: Haryana

Vikas Rathi DCO FDA Haryana

Vijay Raje DCO FDA Haryana

Republic Day 2026 Awards: Punjab

Mrs. Navdeep Kaur, DCO Punjab, Supranational,1st Runners Up.

Republic Day 2026 Awards: Telangana

D. Swetha Bindu, Drugs Inspector, Telangana

Republic Day 2026 Awards: Tripura

Biswajit SinghaRoy,
Inspecting Officer, Tripura

পুরস্কৃত ড্রাগ ইন্সপেক্টিং অফিসার

প্রত্যাশা ত্রিপুরা প্রতিনিধি, ২৬ জানুয়ারী ।। প্রজাতন্ত্র দিবসের দিনে মন্ত্রী সুধাংশু দাসের হাত থেকে পুরস্কার নিলেন ধলাই জেলার ড্রাগ ইন্সপেক্টিং অফিসার বিশ্বজিৎ সিংহা রায়। তার নিষ্ঠা, সততা ও কার্যকর কাজের স্বীকৃতি স্বরূপ এই সম্মান প্রদান করা হয়। উল্লেখ্য, ধলাই জেলার দায়িত্ব গ্রহণের পর থেকেই অবৈধ মাদক ও বেআইনি ওষুধ ব্যবসার বিরুদ্ধে ধারাবাহিকভাবে কঠোর অভিযান চালিয়ে যাচ্ছেন বিশ্বজিৎ সিংহা রায়। অবৈধ ড্রাগের চোরাচালান রুখতে নিয়মিত পরিদর্শন, অভিযান এবং সচেতনতামূলক কার্যক্রমের

মাধ্যমে তিনি জেলার আইনশৃঙ্খলা রক্ষায় গুরুত্বপূর্ণ ভূমিকা পালন করছেন। তার এই নিরলস প্রচেষ্টার ফলে জেলায় অবৈধ ড্রাগের রমরমা অনেকাংশে কমেছে বলে দাবি স্থানীয়দের। সাধারণ মানুষ থেকে শুরু করে প্রশাসনিক মহল সকলেই তার কাজের ভূয়সী প্রশংসা করছেন। অনেকেই মনে করছেন, তার মতো সৎ ও কর্মঠ আধিকারিকের জন্যই ধলাই জেলা আজ অনেকটাই নিরাপদ ও নিয়ন্ত্রিত। রাজ্য সরকারের স্বীকৃতি ধলাই জেলার জন্য যেমন গর্বের, তেমনি ভবিষ্যতে অবৈধ ড্রাগের বিরুদ্ধে লড়াই আরও জোরদার হবে বলেই আশা করছেন সংশ্লিষ্ট মহল।

Respected Sir/Madam,

I am pleased to inform you that I have been honored with the Best Performing Officer-Enforcement category in recognition of my contributions and dedicated service in the field of Drugs control and Quality Assurance of Clinical Establishment. The award was handed over to me by Honourable Minister of Welfare of Scheduled Castes, Animal Resource Development & Fisheries, Government of Tripura in presence of Honourable District Collector & Magaistrate sir, Honourable SP sir, Dhalai Tripura on the occasion of 77th Republic Day Celebration. This achievement would not have been possible without the continuous guidance, support, and encouragement from our organization and respected seniors of DCOIWA. I consider this recognition not only a personal milestone but also a reflection of the collective efforts and values upheld by our team.

I sincerely thank you for your constant support and motivation, which have helped me strive for excellence in my duties. Kindly treat this as an official intimation of the award. I look forward to continuing to serve with the same commitment and dedication.

-Biswajit SinghaRoy

CDSCO | States | NSQ List: December 2025

Click any where to read all the DCOIWA Newsletters

E-Newsletter

DCOIWA News

Drugs Control Officers (I) Welfare Association (Regd)

Click below links to download:

[NSQ: December 2025 CDSCO]

[NSQ: December 2025 STATES]

[NSQ: Year wise]

Source: CDSCO Website

Sub-Standard Drugs

Send your news and articles to:
dcoiwanewsletter@gmail.com

Important Links

Important links

PG Portal

CDSCO

SUGAM Portal

Online System for Medical Devices

State FDAs Portal

NPPA

Jan Aushadhi

Pharmexcil

FSSAI

eCourts

Pharma Sahi Daam

National Medical Commission

Clinical Establishment

Pharmacy Council of India

Important short notes for Industry and Regulators
By Lalit Kr. Goel, FDA Haryana



To read click anywhere in the picture

Key Notes on Revised Schedule M: Compilation
By Rakesh Dahiya, FDA Haryana

To read click anywhere in the picture

FAQs

by
Lalit Kr. Goel
State Drugs Controller,
FDA Haryana

To read all FAQs on various topics, Click the below links

Schedules: All types of Clinical Trials

Schedules

Compiled by
Rakesh Dahiya
FDA Haryana

For Schedules on following topics Click below links

1

Schedules: All types of Clinical Trials under New Drugs and Clinical Trials Rules 2019

As per **New Drugs and Clinical Trials Rules 2019** we have provided all the schedules introduced in these rules. Click below links for more information:

First Schedule – Clinical Trial – General principles and practices for Clinical Trial

First-Schedule-Clinical-Trials

Second Schedule – Clinical Trial – Requirements and guidelines for permission to import or manufacture of New Drug for sale or to undertake clinical trial

Second-Schedule-Clinical-Trials

Third Schedule – Clinical Trial – Conduct of Clinical Trial

Third-Schedule-Clinical-Trials

Fourth Schedule – Clinical Trial – Requirements and guidelines for conduct of bioavailability and

(Continued on page 67)

Schedules: All types of Clinical Trials

Schedules

Compiled by
Rakesh Dahiya
FDA Haryana

For Schedules on following topics Click below links

2

bioequivalence study of New drug or investigational new drug

[Fourth-Schedule-Clinical-Trials]

Fifth Schedule – Clinical Trial – Post market assessment

[Fifth-Schedule-Clinical-Trials]

Sixth Schedule – Clinical Trial – Fee payable for licence, permission and registration certificate

[Sixth-Schedule-Clinical-Trials]

Seventh Schedule – Clinical Trial – Formulae to determine the quantum of compensation in the cases of Clinical Trial related injury or death

[Seventh-Schedule-Clinical-Trials]

Eight Schedule – Clinical Trial – Application Forms

[Eighth-Schedule-Clinical-Trials]

Compiled by:

Rakesh Dahiya

Asstt. State Drugs Controller

FDA Haryana

Click here for more articles of the Author

Pharmaceuticals

Important Notifications

भारत का राजपत्र
The Gazette of India

Important Notifications

Compiled by
Rakesh Dahiya
FDA Haryana

For notifications on following topics Click below links

Latest Notifications

भारत का राजपत्र
The Gazette of India

Drug Rules

GSR 51(E) dt 21-01-2026 Draft Notification **Blue vertical line on labels of Antimicrobial Drugs**

GSR 51(E) dt 21-01-2026 Draft Notification Blue vertical line on labels of Antimicrobial Drugs

GSR 66(E) dt 28-01-2026 Draft Notification for consideration of **Navi Mumbai International Airport (NMIA)** as authorized Airport for Drug Import, under the provision of Rule 43A of Drugs Rules 1945

GSR 66(E) dt 28-01-2026 Draft Notification for consideration of Navi Mumbai International Airport (NMIA) as authorized Airport for Drug Import, under the provision of Rule 43A of Drugs Rules 1945

Send your news and articles to:
dcoiwanewsletter@gmail.com

Latest Notifications

भारत का राजपत्र
The Gazette of India

Clinical Trial

GSR 46(E) dt 20-01-26 Notification about **Changes to requirements of Test License** under **NDCT Rules 2019 NDCT Rules (Amendment) 2026**

GSR 46(E) dt 20-01-26 Notification about Changes to requirements of Test License under NDCT Rules 2019 NDCT Rules (Amendment) 2026



Upcoming Events

2026

April-2026

PharmaTech Expo Chandigarh

Date: April 09-11, 2026
Location: Chandigarh, India
Description: PharmaTech Expo is one of the largest pharma exhibitions in India and is a place for thousands of people from the business to share their experiences related to products, customers, business, and sales. This pharmaceutical and lab expo brings together people from across the globe to one destination. It is one of the biggest B2B trade shows of the sector that involves people from the healthcare and pharma machinery industries to participate and share innovation related to advanced technologies in the pertinent sector. It will showcase pharma products, machinery, and technological innovation to buyers from various countries, including India, China, the USA, & Germany, which are major markets for this sector. This event will surely give you a huge platform to establish and enhance your business by meeting active suppliers looking for collaboration with the Indian pharma and healthcare market. Meeting new investors and fellow businessmen from the same fraternity would definitely be a win-win situation for both parties. If you are from the pharmaceuticals and healthcare industry and want to explore the involution of business, come and be a part of this mega pharma trade fair.

Click for more details

Send your news and articles to:
dcoiwanewsletter@gmail.com

24 DCOIWA News February 2026

DCOIWA Mission

To unite and organize the working and retired Drugs Control Officers from Indian States, Union Territories and CDSCO, with an object of coordinating their activities for establishment of social justice and regulating the relations of the officers with government agencies. Call : 8121296397, 8094357800,9977177574

a) To unite and organize the working and retired Drugs Control Officers from Indian States, Union Territories and CDSCO, with an object of coordinating their activities for establishment of social justice and regulating the relations of the officers with government agencies.
b) To safeguard and promote interest of its members all over the country
c) To redress the grievances of the members.
d) To promote a sense of fraternity, feeling of belonging and brotherhood amongst its members.
e) To cooperate, accept affiliations and federate with the officers associations, federations, and confederations in the country where similar objectives are seen with international bodies.
f) To achieve professional excellence through better coordination amongst its members.
g) To offer better services to the public.
h) To make dedicated efforts for welfare of its members.
i) To conduct seminars, webinars, social activities, competitions, quiz programs etc. time to time.
j) To take up any other activity conducive to the betterment in the discharge of their functions effectively and efficiently.

How to become a member

Register Online **Download Form**

Dear Members,

As we conclude this edition of our e-newsletter, I would like to express my gratitude to our contributors and readers for their continued support. Your engagement is invaluable, and we appreciate the diverse perspectives that make our community thrive.

We strive to bring you relevant and insightful content, and we welcome any feedback or suggestions you may have for future editions. Our goal is to foster a collaborative space for knowledge-sharing among DCOIWA members, regulators, and pharmacy professionals.

Thank you for being a part of our community. We look forward to bringing you more enriching content in the upcoming editions.

Best regards,

Rakesh Dahiya
Editor-in-Chief
DCOIWA News